Nucleic acid compositions for delivery of exogenous polynucleotides and methods of use
By using recombinant Zika virus and Zika virus-like particle vectors, polynucleotides are delivered to central nervous system cells, solving the high toxicity and inefficiency of biologically active compounds in cell delivery, and achieving high efficiency for central nervous system Targeted delivery and potential therapeutic effects.
Patent Information
- Application Number
- CN202380035537.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-22
- Filing Date
- 2023-02-21
- Publication Date
- 2024-12-03
AI Technical Summary
Bioactive compounds face problems of high toxicity and low delivery efficiency in cell delivery, especially when the central nervous system is targeted.
Develop recombinant Zika and Zika-like particles carrying polynucleotides of interest, as well as nucleic acid compositions, using these vectors to deliver the polynucleotide to target cells, including nucleic acids encoding Zika virus structural and non-structural proteins Compositions are delivered to central nervous system cells by lipid encapsulation technology.
It achieves efficient delivery of target cells, reduces toxicity to normal tissues, improves central nervous system targeting, and provides treatment options for potential treatments such as Alzheimer's disease, autism and Parkinson's disease.
Smart Images

Figure CN119072491A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of U.S. Application No. 63 / 312,785, filed on February 22, 2022, the entire contents of which are incorporated herein by reference.
[0003] Sequence Listing
[0004] This application contains a sequence listing submitted in XML format and hereby incorporated by reference in its entirety. The XML copy was created on February 21, 2023, is named 61771-703_601_SL.xml, and is 2,964,424 bytes in size. Background Art
[0005] Cellular delivery of various bioactive compounds (such as antigens and proteins of interest) is of high value for both basic research and industrial applications. However, it is often compromised by two limitations, one is high toxicity to normal tissues, and the other is low delivery efficiency, because living cells are highly restricted by the complex membrane system of cells. Particular difficulties have been observed in delivery efforts targeting the central nervous system (CNS). Summary of the invention
[0006] In one aspect, in order to meet the needs of new delivery methods for target cells, recombinant Zika virus and Zika virus-like particles carrying polynucleotides of interest are provided herein. In some embodiments, the virus and virus-like particles comprise Zika structural proteins. The method of use relates to administering such recombinant Zika virus or such Zika virus-like particles to target cells. In some cases, considering its favorable CNS tropism, such methods of use treat disorders of the central nervous system. In some cases, the virus and virus-like particles do not comprise replicating Zika virus.
[0007] On the other hand, in order to meet the needs of new delivery methods for target cells, transcripts of nucleic acid compositions carrying polynucleotides of interest (e.g., exogenous polynucleotides) and regulatory regions from the Zika genome are provided herein. Exemplary methods of use involve encapsulating such transcripts with lipid-based reagents, and applying such compounds to target cells. In some embodiments, the nucleic acid composition comprises Zika 5'UTR, polynucleotides of interest, and Zika 3'UTR. In some embodiments, the nucleic acid composition does not encode Zika structural proteins. In some embodiments, the nucleic acid composition does not encode Zika non-structural proteins. In some embodiments, the polynucleotides of interest have a size of up to about 5700, 5600, 5500, 5400, 5300, 5200, 5100, 5000, 4900, 4800, 4700, 4600, or 4500 nucleotides. In some embodiments, the polynucleotide of interest has a size of about 10, 20, 30, 40, 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 nucleotides up to about 5700, 5600, 5500, 5400, 5300, 5200, 5100, 5000, 4900, 4800, 4700, 4600, or 4500 nucleotides.
[0008] In some embodiments, the nucleic acid composition comprises (i) a polynucleotide encoding a Zika virus capsid protein (C) or a derivative of Zika virus C, a polynucleotide encoding a Zika virus viral membrane protein (prM / M) or a derivative of Zika virus prM / M, a polynucleotide encoding a Zika virus viral envelope protein (E) or a derivative of Zika virus E, or any combination thereof; and (ii) a polynucleotide exogenous to Zika virus. In some embodiments, the nucleic acid composition comprises a derivative of Zika virus C, wherein the derivative encodes at least or about 5, 10, 15, 20, 25, or 30 amino acids of C. In some embodiments, the nucleic acid composition comprises a derivative of Zika virus C, wherein the derivative encodes about 5, 10, 15, 20, or 25 to about 30 amino acids of C. In some embodiments, the nucleic acid composition comprises a polynucleotide encoding C. In some embodiments, the nucleic acid composition does not encode a polynucleotide encoding a Zika virus viral membrane protein (prM / M) or a derivative of Zika virus prM / M and a polynucleotide encoding a Zika virus viral envelope protein (E) or a derivative of Zika virus E. In some embodiments, the exogenous polynucleotide has a size of up to about 5700, 5600, 5500, 5400, 5300, 5200, 5100, 5000, 4900, 4800, 4700, 4600 or 4500 nucleotides. In some embodiments, the exogenous polynucleotide has a size of about 10, 20, 30, 40, 50, 100, 150, 200, 250, 300, 350, 400, 450 or 500 nucleotides up to a size of about 5700, 5600, 5500, 5400, 5300, 5200, 5100, 5000, 4900, 4800, 4700, 4600 or 4500 nucleotides. In some embodiments, the nucleic acid composition is a delivery vehicle for delivering the exogenous polynucleotide to a target cell of an object. The target cell can be a cell in the central nervous system.
[0009] In some embodiments, the nucleic acid composition comprises a polynucleotide encoding Zika virus C or a derivative of Zika virus C, a polynucleotide encoding Zika virus prM / M or a derivative of Zika virus prM / M, and a polynucleotide encoding Zika virus E or a derivative of Zika virus E. In some embodiments, the polynucleotide encoding Zika virus C or a derivative of Zika virus C, the polynucleotide encoding Zika virus prM / M or a derivative of Zika virus prM / M, and the polynucleotide encoding Zika virus E or a derivative of Zika virus E are expressed on one or more separate nucleic acids.
[0010] In some embodiments, the polynucleotide encoding the derivative of Zika virus C comprises at least one substitution, at least one deletion, and / or at least one insertion compared to wild-type Zika virus C. In some embodiments, Zika virus C or a derivative of Zika virus C comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to a sequence of Table 1A, Table ID, Table II, Table 2, or Table 3. In some embodiments, the derivative of Zika virus C comprises about 5, 10, 15, 20, or 25 to about 30 amino acids of a sequence of Table 1A, Table ID, Table II, Table 2, or Table 3.
[0011] In some embodiments, the polynucleotide encoding the derivative of Zika virus prM / M comprises at least one substitution, at least one deletion and / or at least one insertion compared to wild-type Zika virus prM / M. In some embodiments, Zika virus prM / M or a derivative of Zika virus prM / M comprises a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to a sequence of Table 1A, Table 1F or Table 1K.
[0012] In some embodiments, the polynucleotide encoding the derivative of Zika virus E comprises at least one substitution, at least one deletion, and / or at least one insertion compared to wild-type Zika virus E. In some embodiments, the polynucleotide encoding E is translated into wild-type Zika virus E. In some embodiments, Zika virus E or a derivative of Zika virus E comprises a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a sequence of Table 1A, Table IE, or Table 1J.
[0013] In some embodiments, the nucleic acid composition comprises a 5' untranslated region (5'UTR) of a Zika virus. In some embodiments, a Zika virus 5'UTR or a derivative of a Zika virus 5'UTR comprises a sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to a sequence of Table 1A, Table 1C, Table 1H or Table 2.
[0014] In some embodiments, the nucleic acid composition comprises a 3' untranslated region (3'UTR) of a Zika virus. In some embodiments, a Zika virus 3'UTR or a derivative of a Zika virus 3'UTR comprises a sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to a sequence of Table 1A, Table 1B, Table 1G or Table 2.
[0015] In some embodiments, the nucleic acid composition does not include polynucleotides encoding one or more non-structural (NS) proteins selected from (i) NS1, (ii) NS2A, (iii) NS2B, (iv) NS3, (v) NS4A, (vi) NS4B, (vii) NS5, or (viii) (i)-(vii) Two or more of the proteins. In other embodiments, the nucleic acid composition includes polynucleotides encoding one or more non-structural (NS) proteins selected from (i) NS1, (ii) NS2A, (iii) NS2B, (iv) NS3, (v) NS4A, (vi) NS4B, (vii) NS5, or (viii) (i)-(vii) Two or more of the proteins. In some embodiments, NS1 is Zika virus NS1, NS2A is Zika virus NS2A, NS2B is Zika virus NS2B, NS3 is Zika virus NS3, NS4A is Zika virus NS4A, NS4B is Zika virus NS4B, or NS5 is Zika virus NS5, or any combination of two or more thereof.
[0016] In some embodiments, the components of the nucleic acid composition include an African Zika virus component, an Asian Zika virus component, or a Brazilian Zika virus component, or a combination thereof. In a specific embodiment, the Zika virus is an African MR766 strain.
[0017] In some embodiments, the exogenous polynucleotide is an antigen or an antigenic epitope thereof. In some embodiments, the antigen or its antigenic epitope is disease-associated. In specific embodiments, the antigen or its antigenic epitope is from a pathogen.
[0018] In some embodiments, the pathogen is a virus. In a specific embodiment, the virus is human SARS coronavirus, influenza A virus, influenza B virus, influenza C virus, Ebola virus, hepatitis B virus, hepatitis C virus, herpes simplex virus, human immunodeficiency virus (HIV), human papillomavirus (HPV-6, HPV-11), measles virus, rabies virus, polio virus or yellow fever virus.
[0019] In some embodiments, the pathogen is a bacteria. In a specific embodiment, the bacterium is Acinetobacter baumanii, Aggregatobacter actinomycetemcomitans, Bartonella bacilliformis, Bartonella henselae, Bartonella quintana, Bifidobacterium Borrelia, Bortadella pertussis, Brucella sp, Burkholderia cepacis, Burkholderia psedomallei, Campylobacter jejuni, Cardiobacterium hominis, Campylobacter fetus, Chlamydia pneumonia, Chlymydia trachomatis, Clostridium difficile. difficile), Cyanobacteria, Eikennella corrodens, Enterobacter, Enterococcus faccium, Escherichia coli, Escherichia coli 0157, Franceillatularensis, Fusobacterium nucleatum, Haemophilus influenzae, Haemophilus aphrophilus, Haemophilus ducreyi, Haemophilus parainfluenzae, Helicobacter pylori, Kingella kingae, Klebsiella pneumoniae, Legionella bacteria, Legionella pneumophila serotype 1serogroup1), Leptospira, Morganella morganii, Neisseria gonorrhoeae, Neisseria meningitidis, Proteus mirabilis, Proteus vulgaris, Proteus myxofaciens, Providencia rettgeri, Providencia alcalifaciens, Providencia stuartii, Pseudomonas aeruginosa, Pseudomonas paucimobilis, Pseudomonas putida, Pseudomonas fluorescens, Pseudomonas acidovorans, acidovorans, Rickettsiae, Salmonella enterica, Salmonella typhi, Salmonella paratyphi A, Salmonella paratyphi B, Salmonella dublin, Salmonella arizonae, Salmonella choleraesuis, Serratia marcescens, Schigella dysenteriae, Schigella flexneri, Schigella boydii, Schigella sonnei, Treponema, Stenotrophomonas maltophilia, Vibrio cholerae cholerae), Vibrio mimicus, Vibrio alginolyticus, Vibrio hollisae, Vibrio parahaemolyticus, Vibrio vulnificus, Yersinia pestispestitis), Actinomycetes, Bacillus anthracis, Bacillus subtilis, Clostridium tetani, Clostridium perfingens, Clostridium botulinum, Clostridium tetani, Corynebacterium diphtheriae, Enterococcus faecalis, Enterococcus faecium, Erysipelothrix ruhsiopathiae, Listeria monocytogenes, Mycobacterium leprae, Mycobacterium tuberculosis tuberculosis, Mycoplasma, Nocardia, Propionibacerium, Pseudomonas aeruginosa, Pneumococci, Staphylococcus aureus, Staphylococcus epidermidis, vancomycin resistant Staphylococcus aureus (MRSA), vancomycin resistant Staphylococcus aureus (VRSA), Staphylococcus lugdunensis, Staphylococcus saprophyticus, Streptococcus pneumonia, Streptococcus pyogenes, or Streptococcus mutants.
[0020] In some embodiments, the pathogen is a fungus, an amoeba, or a parasite. In certain embodiments, the fungus, ameba, or parasite is an Acanthamoeba spp., American tryppanosomiasis, Balamuthia mandnillanis, Babesia divergenes, Babesia bigemina, Babesia equi, Babesia microfti, Babesia duncani, Balantidium coli, Blastocystis spp., Cryptosporidium spp., Cyclospora cayetanensis, dientamoeba fragilis, Diphyllobothrium latum, Leishmania amazonensis, Diphyllobothrium spp. ... amazonesis, Naegleria fowderi, Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale curtisi, Plasmodium malariae, Rhinosporidium seeberi, Sarcocystis bovihominis, Sarcocystiss suihominis, Toxoplasma gondii, Trichmonas vaginalis, Trypanosoma brucei, Trypanosoma cruzi, and Taenia multiceps.
[0021] In some embodiments, the exogenous polynucleotide encodes a gene editing tool. In a specific embodiment, the gene editing tool is selected from a large nuclease-related agent, a CRISPR-related agent, a TALEN-related agent, and a zinc finger-related agent.
[0022] In some embodiments, the exogenous polynucleotide is a small interfering RNA (siRNA), an antisense RNA, a microRNA (miRNA), a small or short hairpin RNA (shRNA), a guide RNA (gRNA), a clustered regularly interspaced short palindromic repeat RNA (crRNA), a trans-activated clustered regularly interspaced short palindromic repeat RNA (tracrRNA), an immunostimulatory oligonucleotide, an antisense nucleic acid or a ribozyme. In a specific embodiment, the exogenous polynucleotide targets β-secretase 1 (BACE1) and / or amyloid precursor protein (APP).
[0023] In some embodiments, the exogenous polynucleotide encodes a polypeptide associated with a genetic disorder. In specific embodiments, the polypeptide is brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), enkephalinase inhibitor (NEP), endothelin converting enzyme (ECE), cathepsin B (CTSB), apolipoprotein E 2 (APOE2), SH3 and multi-ankyrin repeat domain protein (SHANK), neural rank protein (NRTN), glial cell line-derived neurotrophic factor (GDNF), brain dopamine neurotrophic factor (CDNF), vascular endothelial growth factor A (VEGF-A) or aromatic L-amino acid decarboxylase (AADC).
[0024] In some embodiments, the exogenous polynucleotide encodes a therapeutic agent or a diagnostic agent. In a specific embodiment, the therapeutic agent is an antibody-based therapeutic agent, a hormone, a cytokine, an inhibitor or antagonist of an immune checkpoint regulator, an agonist of an immunostimulatory molecule or an immune co-stimulatory molecule. In another embodiment, an inhibitor or antagonist of an immune checkpoint regulator is an anti-PD1 antibody. In another embodiment, an antibody-based therapeutic agent is an antibody, a functional fragment of an antibody, a chimeric antigen receptor (CAR) or a T cell receptor (TCR). In other embodiments, the cytokines include lymphokines, monokines, polypeptide hormones, growth hormone, parathyroid hormone, thyroxine, insulin, proinsulin, relaxin, prorelaxin, glycoprotein hormones, follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), luteinizing hormone (LH), liver growth factor, fibroblast growth factor, prolactin, placental lactogen, tumor necrosis factor-a and tumor necrosis factor-β, Mullerian inhibitory substance, mouse gonadotropin-related peptide, inhibin, activin, vascular endothelial growth factor, integrin, thrombopoietin (TPO), nerve growth factor, NGF-β, blood Platelet-derived growth factor, transforming growth factor (TGF), TGF-a, TGF-β, insulin-like growth factor-I and insulin-like growth factor-II, erythropoietin (EPO), osteoinductive factors, interferons (such as interferon-a, interferon-β and interferon-γ), colony stimulating factor (CSF), macrophage-CSF (M-CSF), granulocyte-macrophage-CSF (GM-CSF), granulocyte-CSF (GCSF), interleukin (IL), tumor necrosis factor, TNF-a, TNF-β, LIF or kit ligand (KL), or a combination of two or more thereof.
[0025] In some embodiments, the exogenous polynucleotide is about or up to about 10000, 9000, 8000, 7000, 6000, or 5000 nucleotides long. For example, the exogenous polynucleotide is about 50 to about 10000, 9000, 8000, 7000, 6000, or 5000 nucleotides long.
[0026] In some embodiments, the components of the nucleic acid compositions described herein are expressed on one nucleic acid or two or more separate nucleic acids. In some embodiments, the nucleic acid compositions further comprise one or more expression control elements that are operably linked, which confer expression of the nucleic acid compositions in vitro or in vivo. In some embodiments, the expression control element is a promoter that drives the nucleic acid complex to be expressed in vitro. In specific embodiments, the promoter is T7, T3, SP6 or any phage promoter.
[0027] In some embodiments, the expression control element is a promoter that drives the expression of the nucleic acid complex in the target cell. In some specific embodiments, the promoter is CMV, SV40 or any eukaryotic promoter. In some embodiments, the target cell is a neuron or non-neuronal cell, VERO, COS, CHO, C6 / 36, HeLa, HEK, HepG2. In some embodiments, the target cell is an oligodendrocyte, a microglia or an astrocyte.
[0028] In another aspect, provided herein is a pharmaceutical composition comprising the nucleic acid composition described herein and a pharmaceutically acceptable salt or derivative thereof.
[0029] In another aspect, provided herein is a recombinant Zika virus or Zika virus-like particle produced by expressing a nucleic acid composition described herein in a production cell, wherein the production cell is further infected with a second Zika virus, such that Zika virus C or a derivative of Zika virus C, Zika virus prM / M or a derivative of Zika virus prM / M, and Zika virus E or a derivative of Zika virus E are present in the recombinant Zika virus.
[0030] In some embodiments, the second Zika virus is a wild-type Zika virus. In some embodiments, wild-type Zika viruses are African, Asian, and Brazilian strains. In other embodiments, the second Zika virus is a modified Zika virus. In some specific embodiments, the modified Zika virus comprises one or more microRNA-based gene silencing mechanisms. In some specific embodiments, one or more microRNA-based gene silencing mechanisms control viral replication.
[0031] In another aspect, provided herein is a recombinant Zika virus or Zika virus-like particle produced by expressing a nucleic acid composition as described herein in a production cell in the absence of infection by a second Zika virus, wherein Zika virus C or a derivative of Zika virus C, Zika virus prM / M or a derivative of Zika virus prM / M, and Zika virus E or a derivative of Zika virus E are present in the recombinant Zika virus or Zika virus-like particle.
[0032] In some embodiments, the production cell is Vero E6, HEK, HEK 293T, HEK 293TT, FreeStyle TM 293-F cells, HEK-293.2sus or C6 / 36 cells.
[0033] In some embodiments, the recombinant Zika virus has replication capability. In other embodiments, the recombinant Zika virus is replication incompetent without reducing the vector titer or compromising the expression of exogenous polynucleotides. In some embodiments, the recombinant Zika virus has reduced insertion mutations. In other embodiments, the recombinant Zika virus has a reduced immune response.
[0034] In another aspect, provided herein is a pharmaceutical composition comprising the recombinant Zika virus or Zika virus-like particle described herein, and a pharmaceutically acceptable salt or derivative thereof.
[0035] In another aspect, provided herein is a method for delivering an exogenous polynucleotide to a target cell, the method comprising administering to the target cell a recombinant Zika virus or Zika virus-like particle described herein comprising the exogenous polynucleotide.
[0036] In some embodiments, the target cell is a neuron or a non-neuronal cell. In a specific embodiment, the neuron is an oligodendrocyte, a microglia or an astrocyte. In another specific embodiment, the non-neuronal cell is a prostate epithelial cell, a urothelial cell, a Sertoli cell, a Leydig cell, a spermatogonia or a retinal cell.
[0037] In some embodiments, the methods are performed in vitro, ex vivo, or in vivo.
[0038] In some embodiments, the target cells transiently express the exogenous polynucleotide after delivery. In other embodiments, the target cells continuously express the exogenous polynucleotide after delivery.
[0039] In another aspect, provided herein is a method for treating Alzheimer's disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a recombinant Zika virus or Zika virus-like particle as described herein, wherein the recombinant Zika virus or Zika virus-like particle comprises a polynucleotide encoding brain-derived neurotrophic factor (BDNF).
[0040] In another aspect, provided herein is a method for treating autism in a subject in need thereof, the method comprising administering to the subject an effective amount of a recombinant Zika virus or Zika virus-like particle as described herein, wherein the recombinant Zika virus or Zika virus-like particle comprises a polynucleotide encoding an SH3 and multi-ankyrin repeat domain protein (SHANK).
[0041] In another aspect, provided herein is a method for treating Parkinson's disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a recombinant Zika virus or Zika virus-like particle as described herein, wherein the recombinant Zika virus or Zika virus-like particle comprises a polynucleotide encoding an aromatic L-amino acid decarboxylase (AADC).
[0042] In some embodiments, administration is via systemic delivery.
[0043] In some embodiments, administration is performed intravenously and / or intratumorally.
[0044] In some embodiments, administration is targeted to the intraventricular, cisterna magna, subpial and / or intrathecal cerebrospinal fluid. In other embodiments, administration is not performed within the brain parenchyma.
[0045] In some embodiments, the nucleic acid composition comprises (i) a polynucleotide encoding a ribozyme (ii) a 5' untranslated region (UTR) of Zika virus; (iii) a 3'UTR of Zika virus; and (iv) a polynucleotide exogenous to Zika virus. In some embodiments, the ribozyme is a hammerhead ribozyme or a hepatitis delta virus (HDV) ribozyme. In some embodiments, the nucleic acid further comprises a polynucleotide encoding a second ribozyme. In some specific embodiments, the second ribozyme is a hammerhead ribozyme or a hepatitis delta virus (HDV) ribozyme. In some embodiments, the polynucleotide encoding the ribozyme encodes a hammerhead ribozyme, and the polynucleotide encoding the second ribozyme encodes an HDV ribozyme. In some embodiments, the nucleic acid composition further comprises a C-portion. The C-portion can refer to a portion encoding C, such as a polynucleotide of about 5, 10, 15, 20 or 25 amino acids to about 30 amino acids of C. In some embodiments, the exogenous polynucleotide has a size of up to about 5700, 5600, 5500, 5400, 5300, 5200, 5100, 5000, 4900, 4800, 4700, 4600 or 4500 nucleotides. In some embodiments, the exogenous polynucleotide has a size of about 10, 20, 30, 40, 50, 100, 150, 200, 250, 300, 350, 400, 450 or 500 nucleotides up to a size of about 5700, 5600, 5500, 5400, 5300, 5200, 5100, 5000, 4900, 4800, 4700, 4600 or 4500 nucleotides. In some embodiments, the nucleic acid composition is a delivery vehicle for delivering the exogenous polynucleotide to a target cell in a subject. The target cell can be a cell in the central nervous system.
[0046] In some embodiments, the Zika virus is an African Zika virus, an Asian Zika virus, a Brazilian Zika virus component, or a combination of one or both thereof. In a specific embodiment, the Zika virus is an African MR766 strain.
[0047] In some embodiments, the exogenous polynucleotide is an antigen or an antigenic epitope thereof. In some embodiments, the antigen or its antigenic epitope is disease-associated. In specific embodiments, the antigen or its antigenic epitope is from a pathogen.
[0048] In some embodiments, the pathogen is a virus. In a specific embodiment, the virus is human SARS coronavirus, influenza A virus, influenza B virus, influenza C virus, Ebola virus, hepatitis B virus, hepatitis C virus, herpes simplex virus, human immunodeficiency virus (HIV), human papillomavirus (HPV-6, HPV-11), measles virus, rabies virus, polio virus or yellow fever virus.
[0049] In some embodiments, the pathogen is a bacterium. In a specific embodiment, the bacterium is Acinetobacter baumannii, Actinomycetemcomitans, Bartonella bacilliformis, Bartonella henselae, Bartonella quinquefasciatus, Bifidobacterium borreliae, Bordetella pertussis, Brucella species, Burkholderia cepacia, Burkholderia pseudomallei, Campylobacter jejuni, Cardiomycobacterium sarcoma, Campylobacter fetus, Chlamydia pneumoniae, Chlamydia trachomatis, Clostridium difficile, Cyanobacteria, Eikenella corrodens, Enterobacter, Enterococcus faecalis, Escherichia coli, Escherichia coli 0157, Francisella tularensis, Fusobacterium nucleatum, Flue Haemophilus influenzae, Haemophilus sporophilus, Haemophilus ducreyi, Haemophilus parainfluenzae, Helicobacter pylori, Kingella, Klebsiella pneumoniae, Legionella, Legionella pneumophila serotype 1, Leptospira, Morganella morganii, Neisseria gonorrhoeae, Neisseria meningitidis, Proteus mirabilis, Proteus vulgaris, Proteus viscosus, Providencia rettgeri, Providencia alkaline, Providencia stuartii, Pseudomonas aeruginosa, Pseudomonas paucimobilis, Pseudomonas putida, Pseudomonas fluorescens, Pseudomonas acidovorans, Rickettsia genus, Salmonella enterica, Salmonella typhi, Salmonella paratyphi A, Salmonella paratyphi B, Salmonella dublin, Salmonella arizona, Salmonella choleraesuis, Serratia marcescens, Shigella dysenteriae, Shigella flexneri, Shigella boydii, Shigella sonnei, Treponema spp., Stenotrophomonas maltophilia, Vibrio cholerae, Vibrio mimicus), Vibrio alginolyticus, Vibrio holmenii, Vibrio parahaemolyticus, Vibrio vulnificus, Yersinia pestis, Actinomyces spp., Bacillus anthracis, Bacillus subtilis, Clostridium tetani, Capsule perfringens Clostridium botulinum, Clostridium tetani, Corynebacterium diphtheriae, Enterococcus faecalis, Enterococcus faecium, Erysipelothrix rhusiopathiae, Listeria monocytogenes, Mycobacterium leprae, Mycobacterium tuberculosis, Mycoplasma spp., Nocardia spp., Propionibacterium spp., Pseudomonas aeruginosa, Pneumococcus, Staphylococcus aureus, Staphylococcus epidermidis, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Staphylococcus aureus (VRSA), Staphylococcus lugdunensis, Staphylococcus saprophyticus, Streptococcus pneumoniae, Streptococcus pyogenes, or Streptococcus mutans.
[0050] In some embodiments, the pathogen is a fungus, an amoeba, or a parasite. In specific embodiments, the fungus, an amoeba, or a parasite is an Acanthamoeba species, Chagas disease, Balamuthia baboons, Babesia divergentis, Babesia dimorpha, Babesia equi, Babesia microti, Babesia duncanii, Balantidium coli, Blastocystis species, Cryptosporidium species, Cyclospora, Dienucleate amoeba fragilis, Diphyllobothrium latum, Leishmania amazonensis, Naegleria fowleri, Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale subsp. coli, Plasmodium malariae, Rhinosporidium sieberii, Sarcocystis hominis, Sarcocystis hominis, Toxoplasma gondii, Trichomonas vaginalis, Trypanosoma brucei, Trypanosoma cruzi, and Multicephalus.
[0051] In some embodiments, the exogenous polynucleotide encodes a gene editing tool. In a specific embodiment, the gene editing tool is selected from a large nuclease-related agent, a CRISPR-related agent, a TALEN-related agent, and a zinc finger-related agent.
[0052] In some embodiments, the exogenous polynucleotide is a small interfering RNA (siRNA), an antisense RNA, a microRNA (miRNA), a small or short hairpin RNA (shRNA), a guide RNA (gRNA), a clustered regularly interspaced short palindromic repeat RNA (crRNA), a trans-activated clustered regularly interspaced short palindromic repeat RNA (tracrRNA), an immunostimulatory oligonucleotide, an antisense nucleic acid or a ribozyme. In a specific embodiment, the exogenous polynucleotide targets β-secretase 1 (BACE1) and / or amyloid precursor protein (APP).
[0053] In some embodiments, the exogenous polynucleotide encodes a polypeptide associated with a genetic disorder. In specific embodiments, the polypeptide is brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), enkephalinase inhibitor (NEP), endothelin converting enzyme (ECE), cathepsin B (CTSB), apolipoprotein E 2 (APOE2), SH3 and multi-ankyrin repeat domain protein (SHANK), neural rank protein (NRTN), glial cell line-derived neurotrophic factor (GDNF), brain dopamine neurotrophic factor (CDNF), vascular endothelial growth factor A (VEGF-A) or aromatic L-amino acid decarboxylase (AADC).
[0054] In some embodiments, the exogenous polynucleotide encodes a therapeutic agent or a diagnostic agent. In a specific embodiment, the therapeutic agent is an antibody-based therapeutic agent, a hormone, a cytokine, an inhibitor or antagonist of an immune checkpoint regulator, an agonist of an immunostimulatory molecule or an immune co-stimulatory molecule. In another embodiment, an inhibitor or antagonist of an immune checkpoint regulator is an anti-PD1 antibody. In other embodiments, an antibody-based therapeutic agent is an antibody, a functional fragment of an antibody, a chimeric antigen receptor (CAR) or a T cell receptor (TCR). In other embodiments, the cytokines include lymphokines, monokines, polypeptide hormones, growth hormone, parathyroid hormone, thyroxine, insulin, proinsulin, relaxin, prorelaxin, glycoprotein hormones, follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), luteinizing hormone (LH), liver growth factor, fibroblast growth factor, prolactin, placental lactogen, tumor necrosis factor-a and tumor necrosis factor-β, Mullerian inhibitory substance, mouse gonadotropin-related peptide, inhibin, activin, vascular endothelial growth factor, integrin, thrombopoietin (TPO), nerve growth factor, NGF-β, blood Platelet-derived growth factor, transforming growth factor (TGF), TGF-a, TGF-β, insulin-like growth factor-I and insulin-like growth factor-II, erythropoietin (EPO), osteoinductive factors, interferons (such as interferon-a, interferon-β and interferon-γ), colony stimulating factor (CSF), macrophage-CSF (M-CSF), granulocyte-macrophage-CSF (GM-CSF), granulocyte-CSF (GCSF), interleukin (IL), tumor necrosis factor, TNF-a, TNF-β, LIF or kit ligand (KL), or a combination of two or more thereof.
[0055] In some embodiments, the exogenous polynucleotide is about or up to about 10000, 9000, 8000, 7000, 6000, or 5000 nucleotides long. For example, the exogenous polynucleotide is about 50 to about 10000, 9000, 8000, 7000, 6000, or 5000 nucleotides long.
[0056] In some embodiments, the nucleic acid composition further comprises one or more expression control elements in operable connection, which confer in vitro expression of the nucleic acid composition. In some embodiments, the expression control element is a promoter that drives in vitro expression of the nucleic acid complex. In specific embodiments, the promoter is T7, T3, SP6 or any phage promoter.
[0057] In another aspect, provided herein is a pharmaceutical composition comprising the nucleic acid composition described herein and a pharmaceutically acceptable salt or derivative thereof.
[0058] In another aspect, provided herein is a method of delivering an exogenous polynucleotide to a target cell, the method comprising administering to the target cell a compound produced by a nucleic acid composition as described herein comprising the exogenous polynucleotide.
[0059] In some embodiments, the compound is produced by encapsulating a transcript produced by a nucleic acid composition described herein with a lipid-based agent. In a specific embodiment, the transcript is uncapped. In another specific embodiment, the transcript is produced by in vitro transcription of a nucleic acid composition.
[0060] In some embodiments, the lipid-based agent is a lipofectamine-related agent, a liposome, or a lipid nanoparticle.
[0061] In another aspect, provided herein is a method of triggering or enhancing an immune response in a subject, the method comprising administering to the subject an effective amount of a compound produced by a nucleic acid composition as described herein comprising an antigen or an antigenic epitope thereof.
[0062] In some embodiments, the compound is produced by encapsulating a transcript produced by a nucleic acid composition described herein with a lipid-based agent. In a specific embodiment, the transcript is uncapped. In another specific embodiment, the transcript is produced by in vitro transcription of a nucleic acid composition.
[0063] In some embodiments, the lipid-based agent is a lipofectamine-related agent, a liposome, or a lipid nanoparticle.
[0064] In some embodiments, the administration is performed intramuscularly.
[0065] In some embodiments, the antigen or antigenic epitope thereof is from a pathogen.
[0066] In some embodiments, the pathogen is a virus. In a specific embodiment, the virus is human SARS coronavirus, influenza A virus, influenza B virus, influenza C virus, Ebola virus, hepatitis B virus, hepatitis C virus, herpes simplex virus, human immunodeficiency virus (HIV), human papillomavirus (HPV-6, HPV-11), measles virus, rabies virus, polio virus or yellow fever virus.
[0067] In some embodiments, the pathogen is a bacterium. In a specific embodiment, the bacterium is Acinetobacter baumannii, Actinomycetemcomitans, Bartonella bacilliformis, Bartonella henselae, Bartonella quinquefasciatus, Bifidobacterium borreliae, Bordetella pertussis, Brucella species, Burkholderia cepacia, Burkholderia pseudomallei, Campylobacter jejuni, Cardiomycobacterium sarcoma, Campylobacter fetus, Chlamydia pneumoniae, Chlamydia trachomatis, Clostridium difficile, Cyanobacteria, Eikenella corrodens, Enterobacter, Enterococcus faecalis, Escherichia coli, Escherichia coli 0157, Francisella tularensis, Fusobacterium nucleatum, Flue Haemophilus influenzae, Haemophilus sporophilus, Haemophilus ducreyi, Haemophilus parainfluenzae, Helicobacter pylori, Kingella, Klebsiella pneumoniae, Legionella, Legionella pneumophila serotype 1, Leptospira, Morganella morganii, Neisseria gonorrhoeae, Neisseria meningitidis, Proteus mirabilis, Proteus vulgaris, Proteus viscosus, Providencia rettgeri, Providencia alkaline, Providencia stuartii, Pseudomonas aeruginosa, Pseudomonas paucimobilis, Pseudomonas putida, Pseudomonas fluorescens, Pseudomonas acidovorans, Rickettsia genus, Salmonella enterica, Salmonella typhi, Salmonella paratyphi A, Salmonella paratyphi B, Salmonella dublin, Salmonella arizona, Salmonella choleraesuis, Serratia marcescens, Shigella dysenteriae, Shigella flexneri, Shigella boydii, Shigella sonnei, Treponema spp., Stenotrophomonas maltophilia, Vibrio cholerae, Vibrio mimicus), Vibrio alginolyticus, Vibrio holmenii, Vibrio parahaemolyticus, Vibrio vulnificus, Yersinia pestis, Actinomyces spp., Bacillus anthracis, Bacillus subtilis, Clostridium tetani, Capsule perfringens Clostridium botulinum, Clostridium tetani, Corynebacterium diphtheriae, Enterococcus faecalis, Enterococcus faecium, Erysipelothrix rhusiopathiae, Listeria monocytogenes, Mycobacterium leprae, Mycobacterium tuberculosis, Mycoplasma spp., Nocardia spp., Propionibacterium spp., Pseudomonas aeruginosa, Pneumococcus, Staphylococcus aureus, Staphylococcus epidermidis, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Staphylococcus aureus (VRSA), Staphylococcus lugdunensis, Staphylococcus saprophyticus, Streptococcus pneumoniae, Streptococcus pyogenes, or Streptococcus mutans.
[0068] In some embodiments, the pathogen is a fungus, an amoeba, or a parasite. In specific embodiments, the fungus, an amoeba, or a parasite is an Acanthamoeba species, Chagas disease, Balamuthia baboons, Babesia divergentis, Babesia dimorpha, Babesia equi, Babesia microti, Babesia duncanii, Balantidium coli, Blastocystis species, Cryptosporidium species, Cyclospora, Dienucleate amoeba fragilis, Diphyllobothrium latum, Leishmania amazonensis, Naegleria fowleri, Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale subsp. coli, Plasmodium malariae, Rhinosporidium sieberii, Sarcocystis hominis, Sarcocystis hominis, Toxoplasma gondii, Trichomonas vaginalis, Trypanosoma brucei, Trypanosoma cruzi, and Multicephalus.
[0069] Certain embodiments include a method of delivering a polynucleotide to a target cell in a subject, the method comprising administering a Zika virus or Zika virus-like particle comprising a polynucleotide to the subject, wherein the polynucleotide is not a Zika virus polynucleotide, and the target cell is a cell of the central nervous system. Certain embodiments include a method of delivering a polynucleotide to a subject, the method comprising administering a Zika virus or Zika virus-like particle comprising a polynucleotide to the subject, wherein the polynucleotide is not a Zika virus polynucleotide, and the Zika virus or Zika virus-like particle does not contain a replicating Zika virus. Certain embodiments include a method of delivering a polynucleotide to a subject, the method comprising administering a Zika virus or Zika virus-like particle comprising a polynucleotide to the subject, wherein the polynucleotide is not a Zika virus polynucleotide, and the polynucleotide has a length of up to about 10,000 nucleotides. In some embodiments, the subject suffers from a disease or disorder of the central nervous system. In some embodiments, the polynucleotide has a length greater than about 6000 nucleotides. In some embodiments, the subject is a human or non-human animal.
[0070] Certain embodiments include a Zika virus or a Zika virus-like particle comprising a polynucleotide exogenous to the Zika virus of about 6,000 nucleotides to about 10,000 nucleotides in length, optionally wherein the polynucleotide does not encode a full-length viral structural protein or a full-length viral non-structural protein. In some embodiments, the Zika virus or Zika virus-like particle of claim 7, wherein the Zika virus or Zika virus-like particle is produced by a nucleic acid comprising the polynucleotide. In some embodiments, the nucleic acid further comprises a Zika virus 5'UTR and a Zika virus 3'UTR. In some embodiments, the Zika virus 5'UTR is at least 90% homologous or identical to the Zika virus 5'UTR of Table 2, Table 1A, Table 1C, or Table 1H. In some embodiments, the Zika virus 3'UTR is at least 90% homologous or identical to the Zika virus 3'UTR of Table 2, Table 1A, Table 1B, or Table 1G. In some embodiments, the nucleic acid further comprises a polynucleotide encoding a first ribozyme. In some embodiments, the nucleic acid further comprises a polynucleotide encoding a second ribozyme. In some embodiments, the nucleic acid comprises a polynucleotide encoding a derivative of Zika virus C, wherein the derivative of the Zika virus C is about or less than about 5, 10, 15, 20, 25 or 30 amino acids of Zika virus C. In some embodiments, the nucleic acid does not include a polynucleotide encoding a derivative of Zika virus capsid protein (C) or Zika virus C. In some embodiments, the nucleic acid does not include a polynucleotide encoding a derivative of Zika virus membrane protein (prM / M) or Zika virus prM / M. In some embodiments, the nucleic acid does not include a polynucleotide encoding a derivative of Zika virus envelope protein (E) or Zika virus E. In some embodiments, the nucleic acid does not include a polynucleotide encoding one or more non-structural (NS) proteins: (i) NS1, (ii) NS2A, (iii) NS2B, (iv) NS3, (v) NS4A, (vi) NS4B, (vii) NS5 or (viii) (i)-(vii) two or more polynucleotides. In some embodiments, the nucleic acid further comprises a promoter. In some embodiments, the nucleic acid comprises a sequence of Table 1A-1K, Table 2, or Table 3.
[0071] Certain embodiments include a nucleic acid composition comprising (i) a 5' untranslated region (5'UTR) of a first Zika virus, (ii) a 3'UTR of a second Zika virus, wherein the first Zika virus is optionally the same as the second Zika virus, and (iii) a polynucleotide exogenous to the first Zika virus and the second Zika virus. In some embodiments, the polynucleotide is about 5000 bases to about 10000 bases in length. In some embodiments, the nucleic acid does not include a polynucleotide encoding a derivative of a Zika virus envelope protein (E) or Zika virus E; and the nucleic acid does not include a polynucleotide encoding one or more nonstructural (NS) proteins: (i) NS1, (ii) NS2A, (iii) NS2B, (iv) NS3, (v) NS4A, (vi) NS4B, (vii) NS5, or (viii) (i)-(vii) two or more polynucleotides. In some embodiments, the nucleic acid composition comprises a sequence of Table 1A-1K, Table 2, or Table 3. In some embodiments, the polynucleotides exogenous to the first Zika virus and the second Zika virus are exogenous polynucleotides described herein. BRIEF DESCRIPTION OF THE DRAWINGS
[0072] The novel features of the present invention are particularly set forth in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by referring to the following detailed description and accompanying drawings (also referred to herein as "Figures" and "FIGs") which illustrate illustrative embodiments utilizing the principles of the present invention, in which:
[0073] Figure 1A - Figure E shows a diagram of exemplary replicons described in the present disclosure with different exemplary applications. Figure 1A Replicon structures are shown, which contain vectors or constructs or mRNA as genes expressed without capping. It can include C-part proteins. The replicon contains 2 reporter genes (GFP and Nluc) for proof-of-concept assays. Figure 1B Four possibilities for encapsulation of replicons in delivery are shown. Option 1 is encapsulation via liposomes or nanoparticles for use as a vaccine platform. To maintain native CNS tropism, replicons are derived from wild-type (option 2), or modified Zika virus (option 3), or transfected with a eukaryotic expression vector (option 4) containing a second construct containing additional structural ZIKV proteins. Figure 1C Encapsulation options 2 and 3 are shown, containing both the replicon and the Zika virus genome, comprising recombinant Zika virus that can be used as an anti-cancer therapy. Figure 1D Encapsulation options 2 and 3 containing only the replicon (without the Zika virus genome) are shown, comprising virus-like particles that can be used as viral vectors for CNS gene therapy. Figure 1DVirus-like particles derived from transfection of a eukaryotic expression vector are shown, containing only the replicon RNA (option 4). The encapsulation process is virus-independent.
[0074] Figure 2 A diagram of another exemplary replicon described in the present disclosure is shown compared to a wild-type Zika virus genome.
[0075] Figure 3 Shown are exemplary imaging results of cells transfected with a plasmid carrying a GFP construct.
[0076] Figure 4A-4F Shown is a workflow diagram for the production of recombinant Zika virus by infection of cells expressing the construct with wild-type Zika virus, as well as the results of bright-field microscopy.
[0077] Figure 5 Shown is a plasmid construct comprising: a hammerhead ribozyme of Zika virus; (ii) a 5' untranslated region (UTR) of Zika virus; (iii) a C-portion of Zika virus; (iv) a 3'UTR of Zika virus; (v) a hepatitis delta virus (HDV) ribozyme of Zika virus, and two reporter genes (eGFP) and Nluc.
[0078] Figure 6 Workflow diagram showing RNA transfection of in vitro transcripts and quantification of expression of the exogenous reporter gene Nluc in cell lysates or supernatants of transfected cells.
[0079] Figure 7 The production (steps 1-3) and the delivery and expression of foreign genes (step 4) in Daoy and Vero cells using Zika virus are shown.
[0080] Figure 8 RT PCR from samples 5 days after infection of VERO cells with ZIKV viral vectors is shown. Quantification of RNA copy number present in viral vectors (pREP+ZIKV) was compared to ZIKV (ZIKV infection alone) using pREP-specific TaqMan primers (black bars) and ZIKV (grey bars).
[0081] Fig. 9 The tropism of ZIKVV and the expression of pREP-delivered NanoNuc reporter genes in different cell types are shown. The control group had no virus infection, the ZIKV wild-type group was infected with wild-type Zika virus, and the ZIKVV group was infected with the novel Zika virus vector.
[0082] Fig.10is an exemplary construct comprising the polycistronic luciferase and β-galactosidase genes within the Zika virus 5'UTR and the Zika virus 3'UTR.
[0083] Fig.11 is an exemplary construct comprising a gene encoding a SARS-CoV-2 protein within the Zika virus 5'UTR and the Zika virus 3'UTR.
[0084] Fig.12 Graphs showing luciferase and β-galactosidase quantification in Vero cells after transfection with pREP-Luc / Gal vector compared to control cells (transfected with lipofectamine only) are provided. High levels of NanoLuc and β-galactosidase expression confirm the ability of the ZIKV construct to deliver multiple genes.
[0085] Fig.13 Shown are the results of ELISA for detecting recombinant SARS-CoV-2 spike protein produced in Vero cells after transfection with a pREP mRNA construct containing the gene of interest encoding the spike protein.
[0086] Figure 14A-14E are partial capsid genes with different lengths: 15 bp ( Fig.14A )、30bp( Fig. 14B )、45bp( Fig. 14C )、60bp( Fig.14D ) and 75 bp( Fig.14E ) are exemplary constructs.
[0087] Figure 15A-15B Shown is the difference in the expression of ZIKVV at 6 h post-IP injection ( Fig.15A ) and 48 h after ZIKVV IP injection ( Fig. 15B ) Biodistribution and tropism of ZIKVV in mice.
[0088] Fig.16A pREP RNA encapsidation in all plasmids tested is shown ( Figures 14A-14E , having C-parts of 15 bp, 30 bp, 45 bp, 60 bp, and 75 bp, respectively). In the plasmids with C-parts (having 15 bp, 30 bp, 45 bp, and 60 bp), pREP RNA encapsidation was higher, indicating that ZIKVV carrying pREP RNA with capsids (having 20 or fewer amino acids) was more efficiently encapsidated into viral vectors. Fig. 16B It was shown that encapsulation derived from DNA transfection is highly efficient and that the plasmid with the C-part 45 bp had a higher amount of pREP RNA.
[0089] Figure 17A-17BShown is Nanoluc quantification in Vero cells following contact with viral vectors carrying 5, 10, 15, 20 and 25 amino acids (pREP+ZIKV) derived from RNA ( Fig.17A ) and DNA( Fig. 17B ) transfected both. Compared with the control group, higher levels of NanoLuc expression were demonstrated in viral vectors of all capsid sequence sizes. These results indicate that ZIKVV is able to encapsulate pREP RNA with C-parts (15bp, 30bp, 45bp, 60bp, and 75bp) and deliver NanoLuc, which is confirmed by the expression of reporter genes in target cells. DETAILED DESCRIPTION
[0090] Provided herein are various nucleic acid compositions comprising exogenous polynucleotides. Nucleic acid compositions can be used to deliver exogenous polynucleotides to target cells. Target cells can be cells of the central nervous system. Target cells can be present in an object, wherein nucleic acid compositions deliver exogenous polynucleotides to target cells in an object. Some nucleic acid compositions comprise exogenous polynucleotides up to about 6,000 or 10,000 nucleotides (e.g., about 5 nucleotides to about 6,000 nucleotides) in length. Nucleic acid compositions can include 5' untranslated regions (UTRs) of Zika virus and 3'UTRs of Zika virus, and optionally do not include polynucleotides encoding one or more nonstructural proteins of the virus, and further optionally do not include polynucleotides encoding one or more structural proteins of the virus.
[0091] In one aspect, a nucleic acid composition is provided herein, comprising (i) a polynucleotide encoding a ribozyme (ii) a 5' untranslated region (UTR) of Zika virus; (iii) a 3'UTR of Zika virus; and (iv) a polynucleotide exogenous to Zika virus. In some embodiments, the ribozyme is a hammerhead ribozyme or a hepatitis delta virus (HDV) ribozyme. In some embodiments, the nucleic acid further comprises a polynucleotide encoding a second ribozyme. In some specific embodiments, the second ribozyme is a hammerhead ribozyme or a hepatitis delta virus (HDV) ribozyme. In some embodiments, the polynucleotide encoding the ribozyme encodes a hammerhead ribozyme, and the polynucleotide encoding the second ribozyme encodes an HDV ribozyme. In some embodiments, the nucleic acid composition further comprises a C-part. For example, the C-part is a derivative of C, wherein the derivative encodes a truncation of C (e.g., about or less than about 30, 25, 20, 15, 10 or 5 amino acids).
[0092] In one aspect, a nucleic acid composition is provided herein, comprising a sequence encoding one of the structural proteins from Zika virus or its derivatives using an exogenous polynucleotide. In a non-limiting example, the nucleic acid composition comprises a derivative of Zika capsid protein (C), wherein the derivative encodes a truncation of C (e.g., about or less than about 30, 25, 20, 15, 10 or 5 amino acids).
[0093] Non-limiting exemplary nucleic acids herein can comprise one or more sequences from Tables 1A-1K, Table 2, and Table 3.
[0094] Further provided herein is a recombinant Zika virus or Zika virus-like particle, which comprises all three structural proteins or derivatives thereof from Zika virus (Zika virus capsid protein (C) or a derivative of Zika virus C, a polynucleotide encoding a Zika virus viral membrane protein (prM / M) or a derivative of Zika virus prM / M, a polynucleotide encoding a Zika virus viral envelope protein (E) or a derivative of Zika virus E). Further provided herein is a method of delivering exogenous polynucleotides to target cells using such recombinant Zika virus or such Zika virus-like particles. In a preferred embodiment, such recombinant Zika virus effectively crosses the blood-brain barrier, resulting in a tropism for targeting the central nervous system (CNS). Therefore, in a preferred embodiment, such recombinant Zika virus is used to deliver exogenous polynucleotides to the CNS.
[0095] Before describing the inventive methods and compositions, it should be understood that the disclosure is not limited to the specific methods or compositions described, and therefore may vary. Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those of ordinary skill in the art are generally understood. All publications mentioned herein are incorporated by reference to disclose and describe the methods and / or materials associated with the cited publications. It should be understood that in the event of a conflict, the present disclosure replaces any disclosure incorporated into the publication.
[0096] It will be apparent to those skilled in the art upon reading this disclosure that each of the individual embodiments described and illustrated herein has discrete components and features that can be readily separated or combined with the features of any other several embodiments without departing from the scope or spirit of the present disclosure. Any recited method can be performed in the order of events recited or in any other order that is logically possible.
[0097] In the case of providing a numerical range, unless otherwise stated, each intermediate value between the upper and lower limits of the range is also specifically disclosed to one tenth of the lower limit unit. Each smaller range between the intermediate values in any specified value or specified range is included in this article. The upper and lower limits of these smaller ranges can be independently included in the range or excluded from the range, and each range when any one, no one or two limits are included in the smaller range is also included in this article, but it depends on any specific exclusion limit in the stated range. When the stated range includes one or two limits, the scope of any one or two of the included limits is also included.
[0098] The term "about" or "approximately" can mean that a particular value is within an acceptable error range as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, for example, limitations of the measurement system. For example, depending on the practice of a given value, "about" can mean within 1 or more than 1 standard deviation. Where specific values are described in the application and claims, unless otherwise stated, the term "about" should be assumed to mean an acceptable error range for the specific value, such as ±10% of the value modified by the term "about".
[0099] The terms "individual," "patient," or "subject" may be used interchangeably. None of these terms require or are limited to situations characterized by supervision (e.g., continuous or intermittent) by a health care worker (e.g., a physician, registered nurse, licensed nurse, physician assistant, caregiver, or hospice worker). In some embodiments, the patient, object, or individual may be under the supervision of a health care worker.
[0100] The terms "heterologous nucleic acid sequence" or "foreign nucleic acid sequence" or "transgene" as used herein in relation to a particular virus may refer to a nucleic acid sequence that originates from a source other than the particular virus.
[0101] As referred to herein, the terms "inhibit," "reduce," or "prevent," or any variation of these terms, may include any measurable reduction or complete inhibition to achieve the desired result.
[0102] As used herein, "promoter" can be a control sequence, which is a region in which transcription initiation and rate are controlled in a nucleic acid sequence. In certain embodiments, a promoter can include genetic elements to which regulatory proteins and molecules can bind, such as RNA polymerase and other transcription factors. The terms "operably positioned", "operably connected", "under control" and "under transcriptional control" can mean that a promoter is in the correct functional position and / or direction relative to a nucleic acid sequence to control transcription initiation and / or expression of the sequence. In certain embodiments, a promoter may or may not be used with an "enhancer", which refers to a cis-acting regulatory sequence that participates in transcriptional activation of a nucleic acid sequence.
[0103] As used herein, the term "percentage identical to..." can be a calculation of "homology" or "percentage homology" between two or more nucleotide or amino acid sequences, which can be determined by aligning the sequences for optimal comparison purposes (e.g., gaps can be introduced into the sequence of the first sequence). The nucleotides at the corresponding positions can then be compared, and the percent identity between the two sequences can be a function of the number of identical positions shared by the sequences (i.e., % homology = number of identical positions / total number of positions × 100). For example, a position in the first sequence can be occupied by the same nucleotide as the corresponding position in the second sequence, so the molecules are identical at that position. Taking into account the number of gaps that need to be introduced for optimal alignment of the two sequences and the length of each gap, the percent homology between the two sequences is a function of the number of identical positions shared by the sequences. In some embodiments, the length of the sequence aligned for comparison purposes can be at least about: 30%, 40%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 95% of the length of the reference sequence. Searching can determine the homology between two sequences. Homology can be between the entire length of the two sequences or between parts of the entire length of the two sequences. The two sequences can be genes, nucleotide sequences, protein sequences, peptide sequences, amino acid sequences or fragments thereof. The actual comparison of the two sequences can be completed by well-known methods, for example, using mathematical algorithms. Non-limiting examples of such mathematical algorithms can be described in Karlin, S. and Altschul, S., Proc. Natl. Acad. Sci. USA, 90-5873-5877 (1993). Such algorithms can be incorporated into NBLAST and XBLAST programs (version 2.0), as described in Altschul, S. et al., Nucleic Acids Res., 25: 3389-3402 (1997). When using BLAST and vacant BLAST programs, any relevant parameters of the corresponding program (e.g., NBLAST) can be used. For example, the parameters for sequence comparison can be set to score=100, word length=12, or can be varied (e.g., W=5 or W=20). Other examples include the algorithms of Myers and Miller, CABIOS (1989), ADVANCE, ADAM, BLAT and FASTA. In another embodiment, the percent identity between two amino acid sequences can be accomplished using, for example, the GAP program in the GCG software package (Accelrys, Cambridge, UK).
[0104] The term "subject" may refer to an animal, including but not limited to a primate (e.g., human), cow, sheep, goat, horse, dog, cat, rabbit, rat, or mouse. The terms "subject" and "patient" are used interchangeably herein, e.g., to refer to a mammalian subject, such as a human subject, or a non-human subject.
[0105] The terms "treat", "treating" and "treatment" may be meant to include relieving or eliminating a disorder, disease, or condition; or one or more symptoms associated with a disorder, disease, or condition; or relieving or eradicating one or more causes of the disorder, disease, or condition itself. The desired effects of treatment may include, but are not limited to, preventing the occurrence or recurrence of a disease, alleviating symptoms, reducing any direct or indirect pathological consequences of a disease, preventing metastasis, reducing the rate of disease progression, improving or alleviating the disease state, and alleviating or improving prognosis.
[0106] The term "therapeutically effective amount" may refer to an amount of a compound that, when administered, is sufficient to prevent the development of, or to alleviate to some extent, one or more symptoms of the disorder, disease or condition being treated. The term "therapeutically effective amount" may also refer to an amount of a compound that is sufficient to elicit the biological or medical response of a cell, tissue, system, animal or human that is being sought by a researcher, veterinarian, medical doctor or clinician.
[0107] The terms "pharmaceutically acceptable carrier", "pharmaceutically acceptable excipient", "physiologically acceptable carrier", or "physiologically acceptable excipient" may refer to a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material. A component may be "pharmaceutically acceptable" in the sense that it is compatible with the other ingredients of a pharmaceutical formulation. It may also be suitable for use in contact with tissues or organs of humans and animals without producing undue toxicity, irritation, allergic response, immunogenicity, or other problems or complications, commensurate with a reasonable benefit / risk ratio. See, Remington: The Science and Practice of Pharmacy, 21st ed.; Lippincott Williams & Wilkins: Philadelphia, PA, 2005; Handbook of Pharmaceutical Excipients, 5th ed.; Rowe et al., eds., The Pharmaceutical Press and the American Pharmaceutical Association: 2005; and Handbook of Pharmaceutical Additives, 3rd ed.; Ash and Ash, eds., Gower Publishing Company: 2007; Pharmaceutical Preformulation and Formulation, Gibson, ed., CRC Press LLC: Boca Raton, FL, 2004).
[0108] The term "pharmaceutical composition" may refer to a mixture of a compound disclosed herein with other chemical components such as a diluent or carrier. A pharmaceutical composition may facilitate administration of a compound to an organism. There are a variety of techniques for administering a compound in the art, including but not limited to oral, injection, aerosol, parenteral, and topical administration. A pharmaceutical composition may also be obtained by reacting a compound with an inorganic or organic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.
[0109] The term "Zika virus-like particle" may refer to a nanoscale multiprotein structure that is composed of assembled Zika virus proteins and that mimics the organization and conformation of the Zika virus, but has no viral genetic material and is therefore non-infectious. The Zika virus-like particle may be very similar to the Zika virus.
[0110] In some embodiments, as used herein, a "derivative" of a polypeptide or polynucleotide refers to a sequence that is at least 80% identical to the polypeptide or polynucleotide, respectively. In some embodiments, as used herein, a "derivative" of a polypeptide or polynucleotide refers to a sequence that is at least 80% homologous to the polypeptide or polynucleotide, respectively. In some embodiments, as used herein, a "derivative" of a polypeptide or polynucleotide refers to a sequence that has no or no more than 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid or nucleotide substitutions, insertions or deletions compared to the polypeptide or polynucleotide, respectively.
[0111] Nucleic acid composition
[0112] In one aspect, the present invention provides a nucleic acid composition comprising (i) a polynucleotide encoding a Zika virus capsid protein (C) or a derivative of Zika virus C, a polynucleotide encoding a Zika virus viral membrane protein (prM / M) or a derivative of Zika virus prM / M, a polynucleotide encoding a Zika virus viral envelope protein (E) or a derivative of Zika virus E, or any combination thereof; and (ii) a polynucleotide exogenous to Zika virus.
[0113] In another aspect, provided herein is a nucleic acid composition comprising a Zika virus 5'UTR, a Zika virus 3'UTR, and a polynucleotide foreign to the Zika virus. In some embodiments, the nucleic acid does not comprise: a polynucleotide encoding a Zika virus capsid protein (C) or a derivative of Zika virus C, a polynucleotide encoding a Zika virus viral membrane protein (prM / M) or a derivative of Zika virus prM / M, a polynucleotide encoding a Zika virus viral envelope protein (E) or a derivative of Zika virus E, or any combination thereof.
[0114] Structural and nonstructural proteins from Zika virus
[0115] The wild-type Zika virus genome contains 10.8 kilobases of single-stranded positive RNA, which encodes three structural proteins (C, prM / M and envelope E) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5). In addition, there are short UTRs at both the 5' and 3' ends of the genome. Various embodiments of recombinant Zika viruses comprising at least one or all of the three structural proteins are provided herein. In some embodiments, a nucleic acid for producing recombinant Zika virus is provided, wherein the nucleic acid lacks one or more or all of the polynucleotides encoding Zika virus structural proteins and Zika virus non-structural proteins. The nucleic acid may include Zika virus 5'UTR and Zika virus 3'UTR, as well as exogenous nucleic acids.
[0116] In some embodiments, the nucleic acid composition comprises a polynucleotide encoding Zika virus C, a polynucleotide encoding Zika virus prM / M, and a polynucleotide encoding Zika virus E. When the three structural proteins are expressed as a nucleic acid composition described herein, in some embodiments, they can be expressed in one nucleic acid. When the three structural proteins are expressed as a nucleic acid composition described herein, in other embodiments, they can be expressed in more than one nucleic acid.
[0117] In some embodiments, the polynucleotide encoding the derivative of Zika virus C comprises at least one substitution, at least one deletion, and / or at least one insertion compared to wild-type Zika virus C. In specific embodiments, Zika virus C or a derivative of Zika virus C comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to a sequence of Table 1A, Table ID, Table II, Table 2 or Table 3. In specific embodiments, the nucleic acid composition comprises a derivative of Zika virus C that encodes an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to a wild-type C sequence. In specific embodiments, the nucleic acid composition comprises a derivative of Zika virus C that encodes an amino acid sequence that is at least 95% identical to a wild-type C sequence. In specific embodiments, the nucleic acid composition comprises a derivative of Zika virus C that encodes an amino acid sequence that is at least 96% identical to a wild-type C sequence. In specific embodiments, the nucleic acid composition comprises a derivative of Zika virus C that encodes an amino acid sequence that is at least 97% identical to a wild-type C sequence. In specific embodiments, the nucleic acid composition comprises a derivative of Zika virus C that encodes an amino acid sequence that is at least 98% identical to a wild-type C sequence. In specific embodiments, the nucleic acid composition comprises a derivative of Zika virus C that encodes an amino acid sequence that is at least 99% identical to a wild-type C sequence. In some embodiments, the nucleic acid composition comprises a derivative of Zika virus C that encodes about 5 to about 30 amino acids of a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to a sequence in Table 1A, Table ID, Table II, Table 2, Table 3, or a wild-type Zika virus.
[0118] In some embodiments, the polynucleotide encoding the derivative of Zika virus prM / M comprises at least one substitution, at least one deletion and / or at least one insertion compared to wild-type Zika virus prM / M. In some embodiments, Zika virus prM / M or a derivative of Zika virus prM / M comprises a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of Table 1A, Table 1F or Table 1K. In specific embodiments, the nucleic acid composition comprises a derivative of Zika virus prM / M encoding an amino acid sequence at least 95% identical to the wild-type prM / M sequence. In specific embodiments, the nucleic acid composition comprises a derivative of Zika virus prM / M encoding an amino acid sequence at least 96% identical to the wild-type prM / M sequence. In specific embodiments, the nucleic acid composition comprises a derivative of Zika virus prM / M encoding an amino acid sequence at least 97% identical to the wild-type prM / M sequence. In specific embodiments, the nucleic acid composition comprises a derivative of a Zika virus prM / M that encodes an amino acid sequence at least 98% identical to a wild-type prM / M sequence. In specific embodiments, the nucleic acid composition comprises a derivative of a Zika virus prM / M that encodes an amino acid sequence at least 99% identical to a wild-type prM / M sequence.
[0119] In some embodiments, the polynucleotide encoding the derivative of Zika virus E comprises at least one substitution, at least one deletion and / or at least one insertion compared to wild-type Zika virus E. In some embodiments, the polynucleotide encoding E is translated into wild-type Zika virus E. In some embodiments, Zika virus E or a derivative of Zika virus E comprises a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of Table 1A, Table IE or Table 1J. In a specific embodiment, the nucleic acid composition comprises a derivative of Zika virus E encoding an amino acid sequence at least 95% identical to the wild-type E sequence. In a specific embodiment, the nucleic acid composition comprises a derivative of Zika virus E encoding an amino acid sequence at least 96% identical to the wild-type E sequence. In a specific embodiment, the nucleic acid composition comprises a derivative of Zika virus E encoding an amino acid sequence at least 97% identical to the wild-type E sequence. In a specific embodiment, the nucleic acid composition comprises a derivative of Zika virus E encoding an amino acid sequence at least 98% identical to the wild-type E sequence. In specific embodiments, the nucleic acid composition comprises a derivative of Zika virus E that encodes an amino acid sequence that is at least 99% identical to a wild-type E sequence.
[0120] In some embodiments, the nucleic acid composition comprises the 5' untranslated region (5'UTR) of Zika virus. In some embodiments, the nucleic acid composition comprises the 3' untranslated region (3'UTR) of Zika virus. Non-limiting exemplary untranslated sequences are provided in Table 1A, Table 1B, Table 1C, Table 1G, Table 1H or Table 2. In some embodiments, the Zika virus 5'UTR comprises a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of Table 1A, Table 1C, Table 1H or Table 2. In some embodiments, the Zika virus 3'UTR comprises a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of Table 1A, Table 1B, Table 1G or Table 2.
[0121] In some embodiments, the nucleic acid composition does not include polynucleotides encoding one or more nonstructural (NS) proteins selected from (i) NS1, (ii) NS2A, (iii) NS2B, (iv) NS3, (v) NS4A, (vi) NS4B, (vii) NS5, or (viii) two or more of (i)-(vii). For example, if the nucleic acid does not include such polynucleotides, there is additional space in the composition to accommodate large exogenous polynucleotides (e.g., up to about 10,000 or 6,000 bases).
[0122] In other embodiments, the nucleic acid composition comprises a polynucleotide encoding one or more nonstructural (NS) proteins selected from (i) NS1, (ii) NS2A, (iii) NS2B, (iv) NS3, (v) NS4A, (vi) NS4B, (vii) NS5, or (viii) two or more of (i)-(vii).
[0123] In certain embodiments, the nucleic acid composition comprises a polynucleotide encoding an NS1 protein. In certain embodiments, the nucleic acid composition comprises a polynucleotide encoding an NS2A protein. In certain embodiments, the nucleic acid composition comprises a polynucleotide encoding an NS2B protein. In certain embodiments, the nucleic acid composition comprises a polynucleotide encoding an NS3 protein. In certain embodiments, the nucleic acid composition comprises a polynucleotide encoding an NS4A protein. In certain embodiments, the nucleic acid composition comprises a polynucleotide encoding an NS4B protein. In certain embodiments, the nucleic acid composition comprises a polynucleotide encoding an NS5 protein.
[0124] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS1 and NS2A. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS1 and NS2B. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS1 and NS3. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS1 and NS4A. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS1 and NS4B. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS1 and NS5.
[0125] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS2A and NS2B. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS2A and NS3. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS2A and NS4A. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS2A and NS4B. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS2A and NS5.
[0126] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS2B and NS3. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS2B and NS4A. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS2B and NS4B. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS2B and NS5.
[0127] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS3 and NS4A. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS3 and NS4B. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS3 and NS5.
[0128] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS4A and NS4B. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS4A and NS5.
[0129] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS4B and NS5.
[0130] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS1, NS2A, and NS2B. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS1, NS2A, and NS3. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS1, NS2A, and NS4A. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS1, NS2A, and NS4B. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS1, NS2A, and NS5.
[0131] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS1, NS2B, and NS3. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS1, NS2B, and NS4A. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS1, NS2B, and NS4B. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS1, NS2B, and NS5.
[0132] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS1, NS3, and NS4A. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS1, NS3, and NS4B. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS1, NS3, and NS5.
[0133] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS1, NS4A, and NS4B. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS1, NS4A, and NS5.
[0134] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS1, NS4B, and NS5.
[0135] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS2A, NS2B, and NS3. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS2A, NS2B, and NS4A. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS2A, NS2B, and NS4B. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS2A, NS2B, and NS5.
[0136] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS2A, NS3, and NS4A. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS2A, NS3, and NS4B. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS2A, NS3, and NS5.
[0137] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS2A, NS4A, and NS4B. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS2A, NS4A, and NS5.
[0138] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS2A, NS4B, and NS5.
[0139] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS2B, NS3, and NS4A. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS2B, NS3, and NS4B. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS2B, NS3, and NS5.
[0140] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS2B, NS4A, and NS5.
[0141] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS2B, NS4B, and NS5.
[0142] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS3 and NS4A, and NS5.
[0143] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS3, NS4B, and NS5.
[0144] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding NS4A, NS4B, and NS5.
[0145] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS1, NS2A, and NS2B. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS1, NS2A, and NS3. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS1, NS2A, and NS4A. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS1, NS2A, and NS4B. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS1, NS2A, and NS5.
[0146] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS1, NS2B, and NS3. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS1, NS2B, and NS4A. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS1, NS2B, and NS4B. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS1, NS2B, and NS5.
[0147] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS1, NS3, and NS4A. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS1, NS3, and NS4B. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS1, NS3, and NS5.
[0148] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS1, NS4A, and NS4B. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS1, NS4A, and NS5.
[0149] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS1, NS4B, and NS5.
[0150] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS2A, NS2B, and NS3. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS2A, NS2B, and NS4A. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS2A, NS2B, and NS4B. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS2A, NS2B, and NS5.
[0151] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS2A, NS3, and NS4A. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS2A, NS3, and NS4B. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS2A, NS3, and NS5.
[0152] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS2A, NS4A, and NS4B. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS2A, NS4A, and NS5.
[0153] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS2A, NS4B, and NS5.
[0154] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS2B, NS3, and NS4A. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS2B, NS3, and NS4B. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS2B, NS3, and NS5.
[0155] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS2B, NS4A, and NS5.
[0156] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS2B, NS4B, and NS5.
[0157] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS3 and NS4A, and NS5.
[0158] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS3, NS4B, and NS5.
[0159] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS4A, NS4B, and NS5.
[0160] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS1 and NS2A. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS1 and NS2B. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS1 and NS3. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS1 and NS4A. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS1 and NS4B. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS1 and NS5.
[0161] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS2A and NS2B. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS2A and NS3. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS2A and NS4A. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS2A and NS4B. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS2A and NS5.
[0162] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS2B and NS3. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS2B and NS4A. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS2B and NS4B. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS2B and NS5.
[0163] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS3 and NS4A. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS3 and NS4B. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS3 and NS5.
[0164] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS4A and NS4B. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS4A and NS5.
[0165] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS4B and NS5.
[0166] In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS1. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS2A. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS2B. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS3. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS4A. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS4B. In certain embodiments, the nucleic acid composition comprises polynucleotides encoding all NS proteins except NS5.
[0167] In some embodiments, NS1 is Zika virus NS1. In some embodiments, NS2A is Zika virus NS2A. In some embodiments, NS2B is Zika virus NS2B. In some embodiments, NS3 is Zika virus NS3. In some embodiments, NS4A is Zika virus NS4A. In some embodiments, NS4B is Zika virus NS4B. In some embodiments, NS5 is Zika virus NS5.
[0168] In some embodiments, the nucleic acid composition comprises a derivative of NS1 comprising an amino acid sequence that is at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to the wild-type NS1 sequence of Table 1A. In some embodiments, the nucleic acid composition comprises a derivative of NS2A comprising an amino acid sequence that is at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to the wild-type NS2A sequence of Table 1A. In some embodiments, the nucleic acid composition comprises a derivative of NS2B comprising an amino acid sequence that is at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to the wild-type NS2B sequence of Table 1A. In some embodiments, the nucleic acid composition comprises a derivative of NS3 comprising an amino acid sequence that is at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to the wild-type NS3 sequence of Table 1A. In some embodiments, the nucleic acid composition comprises a derivative of NS4A comprising an amino acid sequence that is at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to the wild-type NS4A sequence of Table 1A. In some embodiments, the nucleic acid composition comprises a derivative of NS4B comprising an amino acid sequence that is at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to the wild-type NS4B sequence of Table 1A. In some embodiments, the nucleic acid composition comprises a derivative of NS5 comprising an amino acid sequence that is at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a wild-type NS5 sequence.
[0169] In some embodiments, the components of the nucleic acid composition include an African Zika virus component, an Asian Zika virus component, or a Brazilian Zika virus component, or a combination thereof. In a specific embodiment, the Zika virus is an African MR766 strain.
[0170] Exogenous polynucleotides
[0171] In some embodiments, the exogenous polynucleotide is about or up to about 10000, 9000, 8000, 7000, 6000 or 5000 nucleotides long. For example, the exogenous polynucleotide is about 50 to about 10000, 9000, 8000, 7000, 6000 or 5000 nucleotides long. The exogenous polynucleotide can be about 100 to about 10000, 9000, 8000, 7000, 6000 or 5000 nucleotides long. The exogenous polynucleotide can be about 50 to about 6000 nucleotides long. The exogenous polynucleotide can be about 100 to about 6000 nucleotides long. The exogenous polynucleotide can be about 50 to about 5000 nucleotides long. The exogenous polynucleotide can be about 100 to about 5000 nucleotides long.
[0172] In some embodiments, the exogenous polynucleotide is about 0.1 kb nucleotides long. In other embodiments, the exogenous sequence is about 0.2 kb long. In other embodiments, the exogenous sequence is about 0.3 kb long. In other embodiments, the exogenous sequence is about 0.4 kb long. In other embodiments, the exogenous sequence is about 0.5 kb long. In other embodiments, the exogenous sequence is about 0.6 kb long. In other embodiments, the exogenous sequence is about 0.7 kb long. In other embodiments, the exogenous sequence is about 0.8 kb long. In other embodiments, the exogenous sequence is about 0.9 kb long. In other embodiments, the exogenous sequence is about 1 kb nucleotides long. In other embodiments, the exogenous polynucleotide is about 2 kb nucleotides long. In some embodiments, the exogenous polynucleotide is about 3 kb nucleotides long. In some embodiments, the exogenous polynucleotide is about 4 kb nucleotides long. In some embodiments, the exogenous polynucleotide is about 5 kb nucleotides long. In some embodiments, the exogenous polynucleotide is about 6 kb nucleotides long. In some embodiments, the exogenous polynucleotide is about 7 kb nucleotides long. In some embodiments, the exogenous polynucleotide is about 8 kb nucleotides long. In some embodiments, the exogenous polynucleotide is about 9 kb nucleotides long. In some embodiments, the exogenous polynucleotide is about 10 kb nucleotides long.
[0173] In some embodiments, the exogenous polynucleotide is an antigen or an antigenic epitope thereof. In some embodiments, the antigen or its antigenic epitope is disease-associated. In specific embodiments, the antigen or its antigenic epitope is from a pathogen.
[0174] In some embodiments, the pathogen is a virus. In a specific embodiment, the virus is human SARS coronavirus, influenza A virus, influenza B virus, influenza C virus, Ebola virus, hepatitis B virus, hepatitis C virus, herpes simplex virus, human immunodeficiency virus (HIV), human papillomavirus (HPV-6, HPV-11), measles virus, rabies virus, polio virus or yellow fever virus.
[0175] In some embodiments, the pathogen is a bacterium. In a specific embodiment, the bacterium is Acinetobacter baumannii, Actinomycetemcomitans, Bartonella bacilliformis, Bartonella henselae, Bartonella quinquefasciatus, Bifidobacterium borreliae, Bordetella pertussis, Brucella species, Burkholderia cepacia, Burkholderia pseudomallei, Campylobacter jejuni, Cardiomycobacterium sarcoma, Campylobacter fetus, Chlamydia pneumoniae, Chlamydia trachomatis, Clostridium difficile, Cyanobacteria, Eikenella corrodens, Enterobacter, Enterococcus faecalis, Escherichia coli, Escherichia coli 0157, Francisella tularensis, Fusobacterium nucleatum, Flue Haemophilus influenzae, Haemophilus sporophilus, Haemophilus ducreyi, Haemophilus parainfluenzae, Helicobacter pylori, Kingella, Klebsiella pneumoniae, Legionella, Legionella pneumophila serotype 1, Leptospira, Morganella morganii, Neisseria gonorrhoeae, Neisseria meningitidis, Proteus mirabilis, Proteus vulgaris, Proteus viscosus, Providencia rettgeri, Providencia alkaline, Providencia stuartii, Pseudomonas aeruginosa, Pseudomonas paucimobilis, Pseudomonas putida, Pseudomonas fluorescens, Pseudomonas acidovorans, Rickettsia genus, Salmonella enterica, Salmonella typhi, Salmonella paratyphi A, Salmonella paratyphi B, Salmonella dublin, Salmonella arizona, Salmonella choleraesuis, Serratia marcescens, Shigella dysenteriae, Shigella flexneri, Shigella boydii, Shigella sonnei, Treponema spp., Stenotrophomonas maltophilia, Vibrio cholerae, Vibrio mimicus), Vibrio alginolyticus, Vibrio holmenii, Vibrio parahaemolyticus, Vibrio vulnificus, Yersinia pestis, Actinomyces spp., Bacillus anthracis, Bacillus subtilis, Clostridium tetani, Capsule perfringens Clostridium botulinum, Clostridium tetani, Corynebacterium diphtheriae, Enterococcus faecalis, Enterococcus faecium, Erysipelothrix rhusiopathiae, Listeria monocytogenes, Mycobacterium leprae, Mycobacterium tuberculosis, Mycoplasma spp., Nocardia spp., Propionibacterium spp., Pseudomonas aeruginosa, Pneumococcus, Staphylococcus aureus, Staphylococcus epidermidis, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Staphylococcus aureus (VRSA), Staphylococcus lugdunensis, Staphylococcus saprophyticus, Streptococcus pneumoniae, Streptococcus pyogenes, or Streptococcus mutans.
[0176] In some embodiments, the pathogen is a fungus, an amoeba, or a parasite. In specific embodiments, the fungus, an amoeba, or a parasite is an Acanthamoeba species, Chagas disease, Balamuthia baboons, Babesia divergentis, Babesia dimorpha, Babesia equi, Babesia microti, Babesia duncanii, Balantidium coli, Blastocystis species, Cryptosporidium species, Cyclospora, Dienucleate amoeba fragilis, Diphyllobothrium latum, Leishmania amazonensis, Naegleria fowleri, Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale subsp. coli, Plasmodium malariae, Rhinosporidium sieberii, Sarcocystis hominis, Sarcocystis hominis, Toxoplasma gondii, Trichomonas vaginalis, Trypanosoma brucei, Trypanosoma cruzi, and Multicephalus.
[0177] In some embodiments, the exogenous polynucleotide encodes a gene editing tool. In a specific embodiment, the gene editing tool is selected from a large nuclease-related agent, a CRISPR-related agent, a TALEN-related agent, and a zinc finger-related agent.
[0178] In some embodiments, the exogenous polynucleotide is a small interfering RNA (siRNA), an antisense RNA, a microRNA (miRNA), a small or short hairpin RNA (shRNA), a guide RNA (gRNA), a clustered regularly interspaced short palindromic repeat RNA (crRNA), a trans-activated clustered regularly interspaced short palindromic repeat RNA (tracrRNA), an immunostimulatory oligonucleotide, an antisense nucleic acid or a ribozyme. In a specific embodiment, the exogenous polynucleotide targets β-secretase 1 (BACE1) and / or amyloid precursor protein (APP).
[0179] In some embodiments, the exogenous polynucleotide encodes a polypeptide associated with a genetic disorder. In specific embodiments, the polypeptide is brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), enkephalinase inhibitor (NEP), endothelin converting enzyme (ECE), cathepsin B (CTSB), apolipoprotein E 2 (APOE2), SH3 and multi-ankyrin repeat domain protein (SHANK), neural rank protein (NRTN), glial cell line-derived neurotrophic factor (GDNF), brain dopamine neurotrophic factor (CDNF), vascular endothelial growth factor A (VEGF-A) or aromatic L-amino acid decarboxylase (AADC).
[0180] In some embodiments, the exogenous polynucleotide encodes a therapeutic agent or a diagnostic agent. In a specific embodiment, the therapeutic agent is an antibody-based therapeutic agent, a hormone, a cytokine, an inhibitor or antagonist of an immune checkpoint regulator, an agonist of an immunostimulatory molecule or an immune co-stimulatory molecule. In another embodiment, an inhibitor or antagonist of an immune checkpoint regulator is an anti-PD1 antibody. In another embodiment, an antibody-based therapeutic agent is an antibody, a functional fragment of an antibody, a chimeric antigen receptor (CAR) or a T cell receptor (TCR). In other embodiments, the cytokines include lymphokines, monokines, polypeptide hormones, growth hormone, parathyroid hormone, thyroxine, insulin, proinsulin, relaxin, prorelaxin, glycoprotein hormones, follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), luteinizing hormone (LH), liver growth factor, fibroblast growth factor, prolactin, placental lactogen, tumor necrosis factor-a and tumor necrosis factor-β, Mullerian inhibitory substance, mouse gonadotropin-related peptide, inhibin, activin, vascular endothelial growth factor, integrin, thrombopoietin (TPO), nerve growth factor, NGF-β, blood Platelet-derived growth factor, transforming growth factor (TGF), TGF-a, TGF-β, insulin-like growth factor-I and insulin-like growth factor-II, erythropoietin (EPO), osteoinductive factors, interferons (such as interferon-a, interferon-β and interferon-γ), colony stimulating factor (CSF), macrophage-CSF (M-CSF), granulocyte-macrophage-CSF (GM-CSF), granulocyte-CSF (GCSF), interleukin (IL), tumor necrosis factor, TNF-a, TNF-β, LIF or kit ligand (KL), or a combination of two or more thereof.
[0181] Additional exemplary features
[0182] In some embodiments, the components of the nucleic acid composition are expressed on one nucleic acid or two or more separate nucleic acids. In some embodiments, the nucleic acid composition further comprises one or more expression control elements that are operably linked, which confer expression of the nucleic acid composition in vitro or in vivo. In some embodiments, the expression control element is a promoter that drives the nucleic acid complex to be expressed in vitro. In specific embodiments, the promoter is T7, T3, SP6 or any phage promoter.
[0183] In some embodiments, the expression control element is a promoter that drives expression of the nucleic acid complex in the target cell. In some specific embodiments, the promoter is CMV, SV40 or any eukaryotic promoter.
[0184] In some embodiments, the target cell is a neuron or non-neuronal cell, VERO, COS, CHO, C6 / 36, HeLa, HEK or HepG2. In some embodiments, the target cell is an oligodendrocyte, a microglia or an astrocyte.
[0185] In some embodiments, provided herein is a pharmaceutical composition comprising the above-mentioned nucleic acid composition and a pharmaceutically acceptable salt or derivative thereof.
[0186] Recombinant Zika virus or Zika virus-like particles
[0187] Viral vectors are widely used in fields such as gene therapy. At present, three key vectors are based on adenovirus, adeno-associated virus and lentivirus. However, there are limitations for each vector. Recombinant Zika virus or Zika virus-like particles are provided herein, which in some embodiments provide more flexible packaging strategies, similar or better delivery efficiency, reduced insertion mutations, reduced immune responses, safety or special tropisms or any combination thereof.
[0188] In some embodiments, the recombinant Zika virus or Zika virus-like particle is produced by expressing a nucleic acid composition described herein in a producer cell, wherein the producer cell is further infected with a second Zika virus such that Zika virus C or a derivative of Zika virus C, Zika virus prM / M or a derivative of Zika virus prM / M, and Zika virus E or a derivative of Zika virus E are present in the recombinant Zika virus or Zika virus-like particle.
[0189] In specific embodiments, the recombinant Zika virus or Zika virus-like particle is produced by a nucleic acid composition comprising only polynucleotides encoding Zika virus C or a derivative of Zika virus C. In additional specific embodiments, the recombinant Zika virus or Zika virus-like particle is produced by a nucleic acid composition that does not encode Zika virus C or a derivative of Zika virus C, does not encode Zika virus prM / M or a derivative of Zika virus prM / M, or does not encode Zika virus E or a derivative of Zika virus E, or any combination of two or more thereof. Thus, in some embodiments, the recombinant Zika virus described herein is produced by expressing such a nucleic acid composition in a producer cell, wherein the producer cell is further infected with a second Zika virus, such that Zika virus C or a derivative of Zika virus C, Zika virus prM / M or a derivative of Zika virus prM / M, and Zika virus E or a derivative of Zika virus E are present in the recombinant Zika virus or Zika virus-like particle.
[0190] In specific embodiments, the recombinant Zika virus or Zika virus-like particle is produced by a nucleic acid composition comprising only polynucleotides encoding Zika virus prM / M or a derivative of Zika virus prM / M. Thus, in some embodiments, the recombinant Zika virus described herein is produced by expressing such a nucleic acid composition in a production cell, wherein the production cell is further infected with a second Zika virus, such that Zika virus C or a derivative of Zika virus C, Zika virus prM / M or a derivative of Zika virus prM / M, and Zika virus E or a derivative of Zika virus E are present in the recombinant Zika virus or Zika virus-like particle.
[0191] In specific embodiments, the recombinant Zika virus or Zika virus-like particle is produced by a nucleic acid composition comprising only a polynucleotide encoding Zika virus E or a derivative of Zika virus E. Thus, in some embodiments, the recombinant Zika virus described herein is produced by expressing such a nucleic acid composition in a producer cell, wherein the producer cell is further infected with a second Zika virus, such that Zika virus C or a derivative of Zika virus C, Zika virus prM / M or a derivative of Zika virus prM / M, and Zika virus E or a derivative of Zika virus E are present in the recombinant Zika virus or Zika virus-like particle.
[0192] In specific embodiments, the recombinant Zika virus or Zika virus-like particle is produced by a nucleic acid composition comprising only a polynucleotide encoding Zika virus C or a derivative of Zika virus C and a polynucleotide encoding Zika virus prM / M or a derivative of Zika virus prM / M. Thus, in some embodiments, the recombinant Zika virus described herein is produced by expressing such a nucleic acid composition in a producer cell, wherein the producer cell is further infected with a second Zika virus, such that Zika virus C or a derivative of Zika virus C, Zika virus prM / M or a derivative of Zika virus prM / M, and Zika virus E or a derivative of Zika virus E are present in the recombinant Zika virus or Zika virus-like particle.
[0193] In specific embodiments, the recombinant Zika virus or Zika virus-like particle is produced by a nucleic acid composition comprising only a polynucleotide encoding Zika virus C or a derivative of Zika virus C and a polynucleotide encoding Zika virus E or a derivative of Zika virus E. Thus, in some embodiments, the recombinant Zika virus described herein is produced by expressing such a nucleic acid composition in a producer cell, wherein the producer cell is further infected with a second Zika virus, such that Zika virus C or a derivative of Zika virus C, Zika virus prM / M or a derivative of Zika virus prM / M, and Zika virus E or a derivative of Zika virus E are present in the recombinant Zika virus or Zika virus-like particle.
[0194] In specific embodiments, the recombinant Zika virus or Zika virus-like particle is produced by a nucleic acid composition comprising only a polynucleotide encoding a Zika virus prM / M or a derivative of a Zika virus prM / M and a polynucleotide encoding a Zika virus E or a derivative of a Zika virus E. Thus, in some embodiments, the recombinant Zika virus described herein is produced by expressing such a nucleic acid composition in a producer cell, wherein the producer cell is further infected with a second Zika virus, such that Zika virus C or a derivative of Zika virus C, Zika virus prM / M or a derivative of Zika virus prM / M, and Zika virus E or a derivative of Zika virus E are present in the recombinant Zika virus or Zika virus-like particle.
[0195] In some embodiments, the second Zika virus for further infection is a wild-type Zika virus. In some embodiments, wild-type Zika viruses are African, Asian and Brazilian strains. In other embodiments, the second Zika virus for further infection is a modified Zika virus. In some specific embodiments, the modified Zika virus comprises one or more microRNA-based gene silencing mechanisms. In some specific embodiments, one or more microRNA-based gene silencing mechanisms control viral replication.
[0196] In some embodiments, recombinant Zika virus or Zika virus-like particles are produced by expressing a nucleic acid described herein in a producer cell in the absence of infection by a second Zika virus, wherein Zika virus C or a derivative of Zika virus C, Zika virus prM / M or a derivative of Zika virus prM / M, and Zika virus E or a derivative of Zika virus E are present in the recombinant Zika virus or Zika virus-like particle.
[0197] In some embodiments, the production cell is Vero E6, HEK, HEK 293T, HEK 293TT, FreeStyle TM 293-F cells, HEK-293.2sus or C6 / 36 cells.
[0198] In some embodiments, the recombinant Zika virus has replication capability. In other embodiments, the recombinant Zika virus is replication incompetent without reducing the vector titer or damaging the expression of exogenous polynucleotides. In some embodiments, the recombinant Zika virus or Zika virus-like particles have reduced insertion mutations. In some embodiments, the recombinant Zika virus or Zika virus-like particles have a reduced immune response. In some embodiments, the Zika virus or Zika virus-like particles have tropism to cells of the central nervous system.
[0199] Methods related to recombinant Zika virus or Zika virus-like particles comprising three structural Zika proteins
[0200] In another aspect, provided herein is a method for delivering an exogenous polynucleotide to a target cell, the method comprising administering a recombinant Zika virus or Zika virus-like particle comprising an exogenous polynucleotide as described herein to the target cell.
[0201] In some embodiments, the target cell is a neuron or a non-neuronal cell. In a specific embodiment, the neuron is an oligodendrocyte, a microglia, or an astrocyte. In another specific embodiment, the non-neuronal cell is a prostate epithelial cell, a urothelial cell, a supporting cell, a Leydig cell, a spermatogonia, or a retinal cell.
[0202] In some embodiments, the methods are performed in vitro, ex vivo, or in vivo.
[0203] In some embodiments, the target cells express the exogenous polynucleotide transiently after delivery. In other embodiments, the target cells express the exogenous polynucleotide continuously after delivery.
[0204] In another aspect, provided herein is a method for treating Alzheimer's disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a recombinant Zika virus or Zika virus-like particle as described herein, wherein the recombinant Zika virus or Zika virus-like particle comprises a polynucleotide encoding brain-derived neurotrophic factor (BDNF).
[0205] In another aspect, provided herein is a method for treating Alzheimer's disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a recombinant Zika virus or Zika virus-like particle as described herein, wherein the recombinant Zika virus or Zika virus-like particle comprises a polynucleotide targeting β-site amyloid precursor protein cleaving enzyme 1 (BACE1).
[0206] In another aspect, provided herein is a method for treating Alzheimer's disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a recombinant Zika virus or Zika virus-like particle as described herein, wherein the recombinant Zika virus or Zika virus-like particle comprises a polynucleotide targeting amyloid precursor protein (APP).
[0207] In another aspect, provided herein is a method for treating Alzheimer's disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a recombinant Zika virus or Zika virus-like particle as described herein, wherein the recombinant Zika virus or Zika virus-like particle comprises a polynucleotide targeting Tau.
[0208] In another aspect, provided herein is a method for treating autism in a subject in need thereof, the method comprising administering to the subject an effective amount of a recombinant Zika virus or Zika virus-like particle as described herein, wherein the recombinant Zika virus or Zika virus-like particle comprises a polynucleotide encoding an SH3 and multi-ankyrin repeat domain protein (SHANK).
[0209] In another aspect, provided herein is a method for treating Parkinson's disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a recombinant Zika virus or Zika virus-like particle as described herein, wherein the recombinant Zika virus or Zika virus-like particle comprises a polynucleotide encoding an aromatic L-amino acid decarboxylase (AADC).
[0210] In another aspect, provided herein is a method for treating Parkinson's disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a recombinant Zika virus or Zika virus-like particle as described herein, wherein the recombinant Zika virus or Zika virus-like particle comprises a polynucleotide encoding human aromatic L-amino acid decarboxylase.
[0211] In another aspect, provided herein is a method for treating Parkinson's disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a recombinant Zika virus or Zika virus-like particle as described herein, the recombinant Zika virus or Zika virus-like particle comprising a polynucleotide encoding a glial cell line-derived neurotrophic factor.
[0212] In another aspect, provided herein is a method of treating / managing Down syndrome in a subject in need thereof, the method comprising administering to the subject an effective amount of a recombinant Zika virus or Zika virus-like particle as described herein, the recombinant Zika virus or Zika virus-like particle comprising a polynucleotide targeting an additional copy of HSA21.
[0213] In another aspect, provided herein is a method for treating choroideremia in a subject in need thereof, the method comprising administering to the subject an effective amount of a recombinant Zika virus or Zika virus-like particle as described herein, wherein the recombinant Zika virus or Zika virus-like particle comprises a polynucleotide encoding rab escort protein 1 (REP1).
[0214] In another aspect, provided herein is a method for treating Leber congenital amaurosis in a subject in need thereof, the method comprising administering to the subject an effective amount of a recombinant Zika virus or Zika virus-like particle as described herein, wherein the recombinant Zika virus or Zika virus-like particle comprises a polynucleotide encoding RPE65.
[0215] In another aspect, provided herein is a method for treating Parkinson's disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a recombinant Zika virus or Zika virus-like particle as described herein, wherein the recombinant Zika virus or Zika virus-like particle comprises a polynucleotide encoding glutamate decarboxylase.
[0216] In another aspect, provided herein is a method for treating ornithine transcarbamylase (OTC) deficiency in a subject in need thereof, the method comprising administering to the subject an effective amount of a recombinant Zika virus or Zika virus-like particle as described herein, the recombinant Zika virus or Zika virus-like particle comprising a polynucleotide encoding ornithine transcarbamylase.
[0217] In another aspect, provided herein is a method of treating multiple sclerosis in a subject in need thereof, the method comprising administering to the subject an effective amount of a recombinant Zika virus or Zika virus-like particle as described herein, wherein the recombinant Zika virus or Zika virus-like particle comprises a polynucleotide encoding interferon-β-1a and 1b.
[0218] In another aspect, provided herein is a method of treating Pompe disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a recombinant Zika virus or Zika virus-like particle as described herein, wherein the recombinant Zika virus or Zika virus-like particle comprises a polynucleotide encoding acid alpha-glucosidase.
[0219] In another aspect, provided herein is a method of treating depression in a subject in need thereof, the method comprising administering to the subject an effective amount of a recombinant Zika virus or Zika virus-like particle as described herein, wherein the recombinant Zika virus or Zika virus-like particle comprises a polynucleotide encoding a selective serotonin reuptake inhibitor.
[0220] In some embodiments, administration is via systemic delivery.
[0221] In some embodiments, administration is performed intravenously and / or intratumorally.
[0222] In some embodiments, administration is targeted to the intraventricular, cisterna magna, subpial and / or intrathecal cerebrospinal fluid. In other embodiments, administration is not performed within the brain parenchyma.
[0223] Dosing and treatment regimen
[0224] The frequency of administration of a pharmaceutical composition containing a recombinant Zika virus or Zika virus-like particle provided herein can vary based on the method being practiced, the physical characteristics of the subject, the severity of the cancer, the type of cancer, and the formulation and means used to administer the composition.
[0225] The duration of treatment will be based on the condition being treated and can be determined by the attending physician. In many cases, the duration of administration varies depending on many factors. Exemplary factors include, but are not limited to, patient response, symptom severity, and cancer type. In some conditions, treatment lasts for days, weeks, or months. In other conditions, complete treatment is achieved by administering one, two, or three doses of the pharmaceutical composition throughout the treatment process. In some aspects, complete treatment can be achieved using a single dose of the pharmaceutical composition.
[0226] In certain embodiments where the patient's status does improve, the dose of the recombinant Zika virus or Zika virus-like particle or pharmaceutical composition thereof described herein being administered may be temporarily reduced or temporarily suspended for a period of time (ie, a "drug holiday").
[0227] In certain embodiments, the dose of the administered composition is temporarily reduced or temporarily suspended for a period of time (ie, a "drug shift").
[0228] In some embodiments, once the patient's condition improves, a maintenance dose is administered (if necessary). Subsequently, in certain embodiments, depending on the symptoms, the dosage, or the frequency of administration, or both are reduced to a level that retains the improved disease, disorder, or condition. However, in certain embodiments, if there is any recurrence of symptoms, the patient requires long-term intermittent treatment.
[0229] The amount of the recombinant Zika virus or Zika virus-like particle provided herein varies according to factors such as the specific virus, the disease condition and its severity, the characteristics of the subject in need of treatment (e.g., weight, sex), but can still be determined based on the specific circumstances surrounding the case. In some embodiments, the desired dose is conveniently present in a single dose or divided doses administered simultaneously (or over a short period of time) or at appropriate intervals, such as two, three, four or more divided doses per day.
[0230] In some embodiments, administration of a recombinant Zika virus or Zika virus-like particle provided herein is titer dependent, and the titer of the recombinant Zika virus or Zika virus-like particle is about 10 6 PFU / mL to about 10 10 PFU / mL.
[0231] In some embodiments, the amount of the recombinant Zika virus or Zika virus-like particle of the present disclosure administered to a subject may be about 10 3 Up to 10 12 infectious virus particles or plaque forming units (PFU).
[0232] In some embodiments, the recombinant Zika virus or Zika virus-like particle of the present disclosure may contain about 10 3Virus particles / dose to about 10 14 The dose is administered at a rate of 1 viral particle / dose.
[0233] In some embodiments, the recombinant Zika virus or Zika virus-like particle of the present disclosure may contain about 10 3 PFU / kg to about 10 14 PFU / kg dose was administered.
[0234] In some embodiments, the recombinant Zika virus or Zika virus-like particle of the present disclosure may contain about 10 3 Virus particles / kg to about 10 14 The dosage of 100 virus particles / kg is administered. Pharmaceutical compositions and formulations of recombinant Zika virus or Zika virus-like particles
[0235] Provided herein are recombinant Zika viruses or Zika virus-like particles formulated into pharmaceutical compositions.
[0236] Pharmaceutical compositions are formulated in a conventional manner using one or more pharmaceutically acceptable inactive ingredients that facilitate processing of active agents into pharmaceutically usable preparations. A summary of pharmaceutical compositions described herein can be found, for example, in Remington: The Science and Practice of Pharmacy, 19th Edition (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, HA and Lachman, L., ed., Pharmaceutical Dosage Forms, Marcel Decker, New York, NY, 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th Edition (Lippincott Williams & Wilkins, 1999), which are incorporated herein by reference for such disclosure. For some viral delivery methods, a pharmaceutically acceptable vehicle is selected from known pharmaceutically acceptable vehicles for delivery, and should be a vehicle in which the virus is stable.
[0237] Further provided herein are pharmaceutical compositions comprising: a virus; a pharmaceutically acceptable inactive ingredient; other medicinal or pharmaceutical agents; a carrier; an adjuvant; a preservative, stabilizer, wetting agent or emulsifier; a solution promoter; a salt; a buffer; an excipient; a binder; a filler; a suspending agent; a flavoring agent; a sweetener; a disintegrant; a dispersant; a surfactant; a lubricant; a colorant; a diluent; a solubilizer; a wetting agent; a plasticizer; a penetration enhancer; an antifoaming agent; an antioxidant; a preservative; or a combination thereof.
[0238] Another aspect of the present disclosure provides a pharmaceutical composition comprising a recombinant Zika virus as described herein. In some embodiments, the pharmaceutical composition may include a solubilizer and an excipient. In some embodiments, the excipient may include one or more of the following: a buffer, a stabilizer, an antioxidant, an adhesive, a diluent, a dispersant, a rate controller, a lubricant, a glidant, a disintegrant, a plasticizer, a preservative, or any combination thereof. In some embodiments, the excipient may include disodium hydrogen phosphate dihydrate, sodium dihydrogen phosphate dihydrate, sodium chloride, inositol, sorbitol, or any combination thereof. In some embodiments, the pharmaceutical composition does not include a preservative. In some embodiments, the pharmaceutical composition may include one or more of a preservative, a diluent, and a carrier. In some embodiments, the pharmaceutical composition may include additional active ingredients or salts thereof. In some embodiments, the solubilizer may be sterile water. In some embodiments, the pharmaceutical composition may include additional active ingredients, wherein the additional active ingredient may be another oncolytic virus.
[0239] Another aspect of the present disclosure provides a method for enhancing the therapeutic effect of an oncolytic virus when the virus is delivered systemically to a subject, the method comprising systemically administering a recombinant Zika virus or Zika virus-like particle as disclosed herein, a recombinant Zika virus or Zika virus-like particle as described herein, or a pharmaceutical composition as disclosed herein.
[0240] Pharmaceutical compositions comprising modified viruses, recombinant Zika viruses or Zika virus-like particles as described herein can be prepared as solutions, dispersions in glycerol, liquid polyethylene glycol, oils, solid dosage forms, inhalable dosage forms, intranasal dosage forms, liposome formulations, dosage forms comprising nanoparticles, dosage forms comprising microparticles, polymer dosage forms or any combination thereof. In some embodiments, pharmaceutical compositions as described herein may include stabilizers and buffers. In some embodiments, pharmaceutical compositions as described herein may include solubilizers, such as sterile water, Tris buffer. In some embodiments, pharmaceutical compositions as described herein may include excipients. Excipients may be excipients described in Handbook of Pharmaceutical Excipients, American Pharmaceutical Association (1986). Non-limiting examples of suitable excipients may include buffers, preservatives, stabilizers, binders, compacting agents, lubricants, chelating agents, dispersion enhancers, disintegrants, flavoring agents, sweeteners, colorants.
[0241] In some embodiments, the excipient may be a buffer. In some embodiments, the excipient may include a preservative. Non-limiting examples of suitable preservatives may include antioxidants and antimicrobial agents. In some embodiments, the pharmaceutical composition as described herein may include a binder as an excipient. In some embodiments, the pharmaceutical composition as described herein may include a lubricant as an excipient. In some embodiments, the pharmaceutical formulation may include a dispersion enhancer as an excipient. In some embodiments, the pharmaceutical composition as described herein may include a disintegrant as an excipient. In some cases, the pharmaceutical composition as described herein may include a chelating agent.
[0242] Also contemplated are combination products comprising one or more recombinant Zika viruses or one or more Zika virus-like particles described herein.
[0243] Under normal storage and use conditions, pharmaceutical compositions as described herein may contain preservatives to prevent microbial growth. In some instances, pharmaceutical compositions as described herein may not contain preservatives. Pharmaceutical forms suitable for injection use may include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injection solutions or dispersions. Prevention of microbial action can be achieved by various antibacterial and antifungal agents.
[0244] For example, for parenteral administration in the aqueous solution, if necessary, liquid dosage forms can be appropriately buffered, and the liquid diluent can be made isotonic with enough saline or glucose.Liquid dosage forms are particularly suitable for intravenous, intramuscular, subcutaneous, intratumoral and intraperitoneal administration.In this respect, according to the present disclosure, the sterile aqueous medium that can be adopted will be known to those skilled in the art.For example, a dosage can be dissolved in 1mL to 20mL isotonic NaCl solution, and added to the fluid (for example, sodium bicarbonate buffered saline) of 100mL to 1000mL, or injected into the infusion site of suggestion.
[0245] In certain embodiments, sterile injection solution can be prepared by mixing the recombinant Zika virus or Zika virus-like particles according to the present disclosure, the recombinant Zika virus or Zika virus-like particles as described herein, or the pharmaceutical composition containing them with the required amount together with the various other ingredients listed above (as required), followed by filtration sterilization. Typically, dispersions are prepared by mixing various sterilized active ingredients into sterile vehicles, which contain the required other ingredients of the basic dispersion medium and those ingredients listed above. Compositions disclosed herein can be prepared in the form of neutral or salt. After preparation, the pharmaceutical composition can be used in a manner compatible with the dosage formulation and in such an amount that is effective for treatment.
[0246] In certain embodiments, the pharmaceutical composition of the present disclosure may include an effective amount of a recombinant virus disclosed herein in combination with a pharmaceutically acceptable carrier. "Pharmaceutically acceptable" as used herein includes any carrier that does not interfere with the effectiveness of the biological activity of the active ingredient and / or is nontoxic to the patient to which it is applied. Non-limiting examples of suitable pharmaceutical carriers include phosphate buffered saline, water, emulsions (such as oil / water emulsions), various types of wetting agents and sterile solutions. Other non-limiting examples of pharmaceutically compatible carriers may include gels, bioabsorbable matrix materials, implant elements, delivery or distribution devices or materials containing recombinant Zika virus or Zika virus-like particles or any other suitable vehicles. Such carriers can be prepared by conventional methods and can be applied to objects in effective amounts.
[0247] Kit for recombinant Zika virus or Zika virus-like particles
[0248] In one aspect of the present disclosure, provided herein are kits comprising one or more reagents or devices for implementing the methods disclosed herein. In some embodiments, the kit comprises a recombinant Zika virus or Zika virus-like particle provided herein. In some embodiments, the kit comprises a device for administering a recombinant Zika virus or Zika virus-like particle provided herein.
[0249] In some embodiments, the kit includes suitable instructions for performing the methods of the kit. The instructions can provide information for performing any method disclosed herein, whether or not the methods can be performed using only the reagents provided in the kit. The kit and instructions may require additional reagents or systems.
[0250] In order to use in the therapeutic applications described herein, kits and articles are also described herein. In some embodiments, such kits include carriers, packaging or containers, which are separated to accommodate one or more containers, such as vials, tubes, etc., each of which includes one of the individual elements to be used in the methods described herein. Suitable containers include, for example, bottles, vials, syringes and test tubes. The container can be formed by a variety of materials such as glass or plastic. The articles provided herein contain packaging materials. Examples of pharmaceutical packaging materials include, but are not limited to, blister packages, bottles, tubes, inhalers, pumps, bags, vials, containers, syringes, bottles, and any packaging materials suitable for selected formulations and the predetermined mode of administration and treatment. The one or more containers optionally have a sterile access port (for example, the container is an intravenous solution bag or a vial with a stopper that can be pierced by a hypodermic needle). Such kits optionally include compositions and identification descriptions or labels or instructions related to their use in the methods described herein.
[0251] The kit will typically include one or more additional containers, each with one or more of the various materials (such as reagents, optionally in concentrated form, and / or devices) required from a commercial and user perspective to use the recombinant Zika virus or Zika virus-like particles described herein. Non-limiting examples of such materials include, but are not limited to, buffers, diluents, fillers, needles, syringes; vehicles, packaging, containers, vials, and / or tube labels listing the contents and / or instructions for use, and package inserts with instructions for use. A set of instructions will also typically be included.
[0252] In some embodiments, the label is on or associated with the container. The label can be on the container when the letters, numbers, or other characters forming the label are attached, molded, or etched into the container itself; the label can be associated with the container, such as as a package insert, when the label is present in a receiver or carrier that also holds the container. The label can be used to indicate that the contents are used for a specific therapeutic application. The label can also indicate instructions for using the contents, such as in the methods described herein.
[0253] In certain embodiments, a pharmaceutical composition comprising a recombinant Zika virus or Zika virus-like particles provided herein and an optional additional active agent is present in a package or dispenser device that may contain one or more unit dosage forms. The package may, for example, comprise a metal or plastic foil, such as a blister package. The package or dispenser device may be accompanied by instructions for use. The package or dispenser may also be accompanied by a notice associated with the container, the form of which is specified by a government agency that manages drug manufacturing, use or sales, and the notice reflects the agency's approval of the form of the drug for human or veterinary administration. For example, such a notice may be a prescription drug label approved by the U.S. Food and Drug Administration, or an approved product insert. Compositions containing recombinant Zika virus or Zika virus-like particles described herein formulated in a compatible pharmaceutical carrier may also be prepared, placed in a suitable container, and labeled for treating a specified condition.
[0254] Nucleic acid compositions comprising regulatory regions of the Zika genome
[0255] The wild-type Zika genome contains several regulatory regions, such as the 5'UTR and 3'UTR. UTRs were found to be important in viral replication and immune regulation. Elements in the UTRs were found to be essential for genome circularization, leading to the initiation of RNA synthesis.
[0256] Ribozymes are self-cleaving RNAs. There are four main types of small ribozyme motifs: hammerhead, hairpin, Varkud satellite (VS), and hepatitis delta virus (HDV).
[0257] In some embodiments, the nucleic acid compositions described herein comprise a polynucleotide encoding a ribozyme. In some embodiments, the Zika virus or Zika virus-like particle described herein comprises a ribozyme.
[0258] In one aspect, the present invention provides a nucleic acid composition comprising (i) a polynucleotide encoding a ribozyme (ii) a 5' untranslated region (UTR) of Zika virus; (iii) a 3'UTR of Zika virus; and (iv) a polynucleotide exogenous to Zika virus. In some embodiments, the ribozyme is a hammerhead ribozyme or an HDV ribozyme. In some embodiments, the nucleic acid further comprises a polynucleotide encoding a second ribozyme. In some specific embodiments, the second ribozyme is a hammerhead ribozyme or a hepatitis delta virus (HDV) ribozyme. In some embodiments, the polynucleotide encoding the ribozyme encodes a hammerhead ribozyme, and the polynucleotide encoding the second ribozyme encodes an HDV ribozyme. In some embodiments, the nucleic acid composition further comprises a C-part.
[0259] In some embodiments, the Zika virus is an African Zika virus, an Asian Zika virus, a Brazilian Zika virus component, or a combination of one or both thereof. In a specific embodiment, the Zika virus is an African MR766 strain.
[0260] Exogenous polynucleotides
[0261] In some embodiments, the exogenous polynucleotide is an antigen or an antigenic epitope thereof. In some embodiments, the antigen or its antigenic epitope is disease-associated. In specific embodiments, the antigen or its antigenic epitope is from a pathogen.
[0262] In some embodiments, the pathogen is a virus. In a specific embodiment, the virus is human SARS coronavirus, influenza A virus, influenza B virus, influenza C virus, Ebola virus, hepatitis B virus, hepatitis C virus, herpes simplex virus, human immunodeficiency virus (HIV), human papillomavirus (HPV-6, HPV-11), measles virus, rabies virus, polio virus or yellow fever virus.
[0263] In some embodiments, the pathogen is a bacterium. In a specific embodiment, the bacterium is Acinetobacter baumannii, Actinomycetemcomitans, Bartonella bacilliformis, Bartonella henselae, Bartonella quinquefasciatus, Bifidobacterium borreliae, Bordetella pertussis, Brucella species, Burkholderia cepacia, Burkholderia pseudomallei, Campylobacter jejuni, Cardiomycobacterium sarcoma, Campylobacter fetus, Chlamydia pneumoniae, Chlamydia trachomatis, Clostridium difficile, Cyanobacteria, Eikenella corrodens, Enterobacter, Enterococcus faecalis, Escherichia coli, Escherichia coli 0157, Francisella tularensis, Fusobacterium nucleatum, Flue Haemophilus influenzae, Haemophilus sporophilus, Haemophilus ducreyi, Haemophilus parainfluenzae, Helicobacter pylori, Kingella, Klebsiella pneumoniae, Legionella, Legionella pneumophila serotype 1, Leptospira, Morganella morganii, Neisseria gonorrhoeae, Neisseria meningitidis, Proteus mirabilis, Proteus vulgaris, Proteus viscosus, Providencia rettgeri, Providencia alkaline, Providencia stuartii, Pseudomonas aeruginosa, Pseudomonas paucimobilis, Pseudomonas putida, Pseudomonas fluorescens, Pseudomonas acidovorans, Rickettsia genus, Salmonella enterica, Salmonella typhi, Salmonella paratyphi A, Salmonella paratyphi B, Salmonella dublin, Salmonella arizona, Salmonella choleraesuis, Serratia marcescens, Shigella dysenteriae, Shigella flexneri, Shigella boydii, Shigella sonnei, Treponema spp., Stenotrophomonas maltophilia, Vibrio cholerae, Vibrio mimicus), Vibrio alginolyticus, Vibrio holmenii, Vibrio parahaemolyticus, Vibrio vulnificus, Yersinia pestis, Actinomyces spp., Bacillus anthracis, Bacillus subtilis, Clostridium tetani, Capsule perfringens Clostridium botulinum, Clostridium tetani, Corynebacterium diphtheriae, Enterococcus faecalis, Enterococcus faecium, Erysipelothrix rhusiopathiae, Listeria monocytogenes, Mycobacterium leprae, Mycobacterium tuberculosis, Mycoplasma spp., Nocardia spp., Propionibacterium spp., Pseudomonas aeruginosa, Pneumococcus, Staphylococcus aureus, Staphylococcus epidermidis, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Staphylococcus aureus (VRSA), Staphylococcus lugdunensis, Staphylococcus saprophyticus, Streptococcus pneumoniae, Streptococcus pyogenes, or Streptococcus mutans.
[0264] In some embodiments, the pathogen is a fungus, an amoeba, or a parasite. In specific embodiments, the fungus, an amoeba, or a parasite is an Acanthamoeba species, Chagas disease, Balamuthia baboons, Babesia divergentis, Babesia dimorpha, Babesia equi, Babesia microti, Babesia duncanii, Balantidium coli, Blastocystis species, Cryptosporidium species, Cyclospora, Dienucleate amoeba fragilis, Diphyllobothrium latum, Leishmania amazonensis, Naegleria fowleri, Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale subsp. coli, Plasmodium malariae, Rhinosporidium sieberii, Sarcocystis hominis, Sarcocystis hominis, Toxoplasma gondii, Trichomonas vaginalis, Trypanosoma brucei, Trypanosoma cruzi, and Multicephalus.
[0265] In some embodiments, the exogenous polynucleotide encodes a gene editing tool. In a specific embodiment, the gene editing tool is selected from a large nuclease-related agent, a CRISPR-related agent, a TALEN-related agent, and a zinc finger-related agent.
[0266] In some embodiments, the exogenous polynucleotide is a small interfering RNA (siRNA), an antisense RNA, a microRNA (miRNA), a small or short hairpin RNA (shRNA), a guide RNA (gRNA), a clustered regularly interspaced short palindromic repeat RNA (crRNA), a trans-activated clustered regularly interspaced short palindromic repeat RNA (tracrRNA), an immunostimulatory oligonucleotide, an antisense nucleic acid or a ribozyme. In a specific embodiment, the exogenous polynucleotide targets β-secretase 1 (BACE1) and / or amyloid precursor protein (APP).
[0267] In some embodiments, the exogenous polynucleotide encodes a polypeptide associated with a genetic disorder. In specific embodiments, the polypeptide is brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), enkephalinase inhibitor (NEP), endothelin converting enzyme (ECE), cathepsin B (CTSB), apolipoprotein E 2 (APOE2), SH3 and multi-ankyrin repeat domain protein (SHANK), neural rank protein (NRTN), glial cell line-derived neurotrophic factor (GDNF), brain dopamine neurotrophic factor (CDNF), vascular endothelial growth factor A (VEGF-A) or aromatic L-amino acid decarboxylase (AADC).
[0268] In some embodiments, the exogenous polynucleotide encodes a therapeutic agent or a diagnostic agent. In a specific embodiment, the therapeutic agent is an antibody-based therapeutic agent, a hormone, a cytokine, an inhibitor or antagonist of an immune checkpoint regulator, an agonist of an immunostimulatory molecule or an immune co-stimulatory molecule. In another embodiment, an inhibitor or antagonist of an immune checkpoint regulator is an anti-PD1 antibody. In another embodiment, an antibody-based therapeutic agent is an antibody, a functional fragment of an antibody, a chimeric antigen receptor (CAR) or a T cell receptor (TCR). In other embodiments, the cytokines include lymphokines, monokines, polypeptide hormones, growth hormone, parathyroid hormone, thyroxine, insulin, proinsulin, relaxin, prorelaxin, glycoprotein hormones, follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), luteinizing hormone (LH), liver growth factor, fibroblast growth factor, prolactin, placental lactogen, tumor necrosis factor-a and tumor necrosis factor-β, Mullerian inhibitory substance, mouse gonadotropin-related peptide, inhibin, activin, vascular endothelial growth factor, integrin, thrombopoietin (TPO), nerve growth factor, NGF-β, blood Platelet-derived growth factor, transforming growth factor (TGF), TGF-a, TGF-β, insulin-like growth factor-1 and insulin-like growth factor-II, erythropoietin (EPO), osteoinductive factors, interferons (such as interferon-a, interferon-β and interferon-γ), colony stimulating factor (CSF), macrophage-CSF (M-CSF), granulocyte-macrophage-CSF (GM-CSF), granulocyte-CSF (GCSF), interleukin (IL), tumor necrosis factor, TNF-a, TNF-β, LIF or kit ligand (KL), or a combination of two or more thereof.
[0269] In some embodiments, the exogenous polynucleotide is about or up to about 10000, 9000, 8000, 7000, 6000 or 5000 nucleotides long. For example, the exogenous polynucleotide is about 50 to about 10000, 9000, 8000, 7000, 6000 or 5000 nucleotides long. The exogenous polynucleotide can be about 100 to about 10000, 9000, 8000, 7000, 6000 or 5000 nucleotides long. The exogenous polynucleotide can be about 50 to about 6000 nucleotides long. The exogenous polynucleotide can be about 100 to about 6000 nucleotides long. The exogenous polynucleotide can be about 50 to about 5000 nucleotides long. The exogenous polynucleotide can be about 100 to about 5000 nucleotides long.
[0270] In some embodiments, the exogenous polynucleotide is about 0.1 kb nucleotides long. In other embodiments, the exogenous sequence is about 0.2 kb long. In other embodiments, the exogenous sequence is about 0.3 kb long. In other embodiments, the exogenous sequence is about 0.4 kb long. In other embodiments, the exogenous sequence is about 0.5 kb long. In other embodiments, the exogenous sequence is about 0.6 kb long. In other embodiments, the exogenous sequence is about 0.7 kb long. In other embodiments, the exogenous sequence is about 0.8 kb long. In other embodiments, the exogenous sequence is about 0.9 kb long. In other embodiments, the exogenous sequence is about 1 kb nucleotides long. In other embodiments, the exogenous polynucleotide is about 2 kb nucleotides long. In some embodiments, the exogenous polynucleotide is about 3 kb nucleotides long. In some embodiments, the exogenous polynucleotide is about 4 kb nucleotides long. In some embodiments, the exogenous polynucleotide is about 5 kb nucleotides long. In some embodiments, the exogenous polynucleotide is about 6 kb nucleotides long. In some embodiments, the exogenous polynucleotide is about 7kb nucleotides long. In some embodiments, the exogenous polynucleotide is about 8kb nucleotides long. In some embodiments, the exogenous polynucleotide is about 9kb nucleotides long. In some embodiments, the exogenous polynucleotide is about 10kb nucleotides long. In some embodiments, the exogenous polynucleotide is about 11kb nucleotides long. In some embodiments, the exogenous polynucleotide is about 12kb nucleotides long. In some embodiments, the exogenous polynucleotide is about 13kb nucleotides long. In some embodiments, the exogenous polynucleotide is about 14kb nucleotides long. In some embodiments, the exogenous polynucleotide is about 15kb nucleotides long. In some embodiments, the exogenous polynucleotide is about 16kb nucleotides long. In some embodiments, the exogenous polynucleotide is about 17kb nucleotides long. In some embodiments, the exogenous polynucleotide is about 18kb nucleotides long. In some embodiments, the exogenous polynucleotide is about 19kb nucleotides long. In some embodiments, the exogenous polynucleotide is about 20kb nucleotides long.
[0271] Additional features of nucleic acid compositions comprising regulatory regions of the Zika genome
[0272] In some embodiments, the nucleic acid composition further comprises one or more operably linked expression control elements that confer in vitro expression of the nucleic acid composition. In some embodiments, the expression control element is a promoter that drives in vitro expression of the nucleic acid complex. In specific embodiments, the promoter is T7, T3, SP6 or any phage promoter.
[0273] In another aspect, provided herein is a pharmaceutical composition comprising the nucleic acid composition described herein and a pharmaceutically acceptable salt or derivative thereof.
[0274] Methods of using nucleic acid compositions
[0275] In another aspect, provided herein is a method of delivering an exogenous polynucleotide to a target cell, the method comprising administering to the target cell a compound produced by a nucleic acid composition as described herein comprising the exogenous polynucleotide.
[0276] In some embodiments, the compound is produced by encapsulating a transcript produced by a nucleic acid composition described herein with a lipid-based agent. In a specific embodiment, the transcript is uncapped. In another specific embodiment, the transcript is produced by in vitro transcription of a nucleic acid composition.
[0277] In some embodiments, the lipid-based agent is a lipofectamine-related agent, a liposome, or a lipid nanoparticle.
[0278] In some embodiments, the lipid-based agents described herein are cationic lipids, neutral lipids, and polyethylene glycol conjugates, such as PEG-diacylglycerol, PEG-diacylsugaramide, PEG-cholesterol or PEG-DMB conjugates, cholesterol, or cholesterol derivatives.
[0279] Suitable cationic lipids include those that carry a net negative charge at a selected pH, such as physiological pH. Particularly useful cationic lipids include those with relatively small head groups, such as tertiary amine, quaternary amine or guanidine head groups, and sterically hindered asymmetric lipid chains. In any of the embodiments described herein, the cationic lipid can be N,N-dioleyl-N,N-dimethylammonium chloride (DODAC), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N-(1-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP), N-(1-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTMA), N,N-dimethyl-2,3-dioleyloxy)propylamine (DODMA), 1,2-dioleoyl-3-dimethylammonium-propane (DODAP), 1,2-dioleoylcarbamoyl-3-dimethylammonium-propane (DOCDAP), 1,2-dilinoleoyl-3-dimethylammonium-propane (DLINDAP), dioleoyloxy-N-[2-sperminecarboxamido)ethyl}-N,N-dimethyl-1-propylamine trimethylamine ... fluoroacetate (DOSPA), dioctadecylamidoglycyl spermine (DOGS), DC-Chol, 1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethylammonium bromide (DMRIE), 3-dimethylamino-2-(cholest-5-en-3-β-oxybut-4-oxy)-1-(cis,cis-9,12-octadecadienyloxy)propane (CLinDMA), 2-[5'-(cholest-5-en-3β-oxy)-3'-oxapentyloxy)-3-dimethyl-1-(cis,cis-9',12'-octadecadienyloxy)propane (CpLinDMA), N,N-dimethyl-3,4-dioleyloxybenzylamine (DMOBA), 1,2-N,N'-dioleylcarbamoyl-3-dimethylaminopropane (DOcarbDAP) and / or mixtures thereof, and other cationic lipids sharing similar properties. The above-mentioned cationic lipids may include various salts as known in the art.
[0280] In some embodiments, the head group of the cationic lipid can be connected to the lipid chain via a cleavable linker or a non-cleavable linker (such as described herein or otherwise known in the art). Non-limiting examples of suitable linkers include those comprising C1 to C10 alkyl, alkyl ether, polyether, polyethylene glycol, acetal, amide, carbonyl, urea, carbamate, carbonate, ester (i.e., monoester, diester) or succinyl.
[0281] Suitable neutral lipids include those comprising any one of various neutral uncharged, zwitterionic lipids or anionic lipids capable of producing stable complexes. They are preferably neutral, although they can be alternatively positively charged or negatively charged. In any embodiment described herein, suitable neutral lipids include those selected from the following substances: compounds with formula NLI-NLVII, dioleoylphosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), egg yolk phosphatidylcholine (EPC), distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), -phosphatidylethanolamine (POPE) and dioleoylphosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal), cholesterol and other neutral lipids described below, and / or mixtures thereof.
[0282] Suitable polyethylene glycol-diacylglycerol or polyethylene glycol-diacylsugaramide (PEG-DAG) conjugates include those comprising a dialkylglycerol or dialkylsugaramide group having an alkyl chain length independently comprising about C4 to about C40 saturated or unsaturated carbon atoms. The dialkylglycerol or dialkylsugaramide group may further comprise one or more substituted alkyl groups. In any of the embodiments described herein, the PEG conjugate can be selected from PEG-dilaurylglycerol (C12), PEG-dimyristylglycerol (C14), PEG-dipalmitoylglycerol (C16), PEG-distearylglycerol (C18), PEG-dilaurylamide (C12), PEG-dimyristylamide (C14), PEG-dipalmitoylamide (C16) and PEG-distearylamide (C18), PEG-cholesterol (1-[8'-(cholest-5-en-3β-oxy)formamido-3',6'-dioxaoctyl]carbamoyl-ω-methyl-poly(ethylene glycol) and PEG-DMB (3,4-tetracosyloxybenzyl-ω-methyl-poly(ethylene glycol) ether).
[0283] In another aspect, provided herein is a method of triggering or enhancing an immune response in a subject, the method comprising administering to the subject an effective amount of a compound produced by a nucleic acid composition as described herein comprising an antigen or an antigenic epitope thereof.
[0284] In some embodiments, the compound is produced by encapsulating a transcript produced by a nucleic acid composition described herein with a lipid-based agent. In a specific embodiment, the transcript is uncapped. In another specific embodiment, the transcript is produced by in vitro transcription of a nucleic acid composition.
[0285] In some embodiments, the lipid-based agent is a lipofectamine-related agent, a liposome, or a lipid nanoparticle.
[0286] In some embodiments, the administration is performed intramuscularly.
[0287] In some embodiments, the antigen or antigenic epitope thereof is from a pathogen.
[0288] In some embodiments, the pathogen is a virus. In a specific embodiment, the virus is human SARS coronavirus, influenza A virus, influenza B virus, influenza C virus, Ebola virus, hepatitis B virus, hepatitis C virus, herpes simplex virus, human immunodeficiency virus (HIV), human papillomavirus (HPV-6, HPV-11), measles virus, rabies virus, polio virus or yellow fever virus.
[0289] In some embodiments, the pathogen is a bacterium. In a specific embodiment, the bacterium is Acinetobacter baumannii, Actinomycetemcomitans, Bartonella bacilliformis, Bartonella henselae, Bartonella quinquefasciatus, Bifidobacterium borreliae, Bordetella pertussis, Brucella species, Burkholderia cepacia, Burkholderia pseudomallei, Campylobacter jejuni, Cardiomycobacterium sarcoma, Campylobacter fetus, Chlamydia pneumoniae, Chlamydia trachomatis, Clostridium difficile, Cyanobacteria, Eikenella corrodens, Enterobacter, Enterococcus faecalis, Escherichia coli, Escherichia coli 0157, Francisella tularensis, Fusobacterium nucleatum, Flue Haemophilus influenzae, Haemophilus sporophilus, Haemophilus ducreyi, Haemophilus parainfluenzae, Helicobacter pylori, Kingella, Klebsiella pneumoniae, Legionella, Legionella pneumophila serotype 1, Leptospira, Morganella morganii, Neisseria gonorrhoeae, Neisseria meningitidis, Proteus mirabilis, Proteus vulgaris, Proteus viscosus, Providencia rettgeri, Providencia alkaline, Providencia stuartii, Pseudomonas aeruginosa, Pseudomonas paucimobilis, Pseudomonas putida, Pseudomonas fluorescens, Pseudomonas acidovorans, Rickettsia genus, Salmonella enterica, Salmonella typhi, Salmonella paratyphi A, Salmonella paratyphi B, Salmonella dublin, Salmonella arizona, Salmonella choleraesuis, Serratia marcescens, Shigella dysenteriae, Shigella flexneri, Shigella boydii, Shigella sonnei, Treponema spp., Stenotrophomonas maltophilia, Vibrio cholerae, Vibrio mimicus), Vibrio alginolyticus, Vibrio holmenii, Vibrio parahaemolyticus, Vibrio vulnificus, Yersinia pestis, Actinomyces spp., Bacillus anthracis, Bacillus subtilis, Clostridium tetani, Capsule perfringens Clostridium botulinum, Clostridium tetani, Corynebacterium diphtheriae, Enterococcus faecalis, Enterococcus faecium, Erysipelothrix rhusiopathiae, Listeria monocytogenes, Mycobacterium leprae, Mycobacterium tuberculosis, Mycoplasma spp., Nocardia spp., Propionibacterium spp., Pseudomonas aeruginosa, Pneumococcus, Staphylococcus aureus, Staphylococcus epidermidis, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Staphylococcus aureus (VRSA), Staphylococcus lugdunensis, Staphylococcus saprophyticus, Streptococcus pneumoniae, Streptococcus pyogenes, or Streptococcus mutans.
[0290] In some embodiments, the pathogen is a fungus, an amoeba, or a parasite. In specific embodiments, the fungus, an amoeba, or a parasite is an Acanthamoeba species, Chagas disease, Balamuthia baboons, Babesia divergentis, Babesia dimorpha, Babesia equi, Babesia microti, Babesia duncanii, Balantidium coli, Blastocystis species, Cryptosporidium species, Cyclospora, Dienucleate amoeba fragilis, Diphyllobothrium latum, Leishmania amazonensis, Naegleria fowleri, Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale subsp. coli, Plasmodium malariae, Rhinosporidium sieberii, Sarcocystis hominis, Sarcocystis hominis, Toxoplasma gondii, Trichomonas vaginalis, Trypanosoma brucei, Trypanosoma cruzi, and Multicephalus.
[0291] Non-limiting exemplary embodiments
[0292] 1. A nucleic acid composition, comprising (i) a polynucleotide encoding a Zika virus 5'UTR or a derivative of the Zika virus 5'UTR, a polynucleotide encoding a Zika virus 3'UTR or a derivative of the Zika virus 3'UTR, a polynucleotide encoding a Zika virus capsid protein (C) or a derivative of Zika virus C, a polynucleotide encoding a Zika virus viral membrane protein (prM / M) or a derivative of Zika virus prM / M, a polynucleotide encoding a Zika virus viral envelope protein (E) or a derivative of Zika virus E, or any combination thereof; and (ii) a polynucleotide exogenous to the Zika virus.
[0293] 2. A nucleic acid composition according to embodiment 1, wherein the nucleic acid composition comprises the polynucleotide encoding the Zika virus 5'UTR, the polynucleotide encoding the Zika virus 3'UTR, the polynucleotide encoding the Zika virus C or the derivative of the Zika virus C, the polynucleotide encoding the Zika virus prM / M or the derivative of the Zika virus prM / M, and the polynucleotide encoding the Zika virus E or the derivative of the Zika virus E.
[0294] 3. A nucleic acid composition according to embodiment 1 or embodiment 2, wherein the polynucleotide encoding the Zika virus 5'UTR or a derivative of the Zika virus 5'UTR, the polynucleotide encoding the Zika virus 3'UTR or a derivative of the Zika virus 3'UTR, the polynucleotide encoding the Zika virus C or the derivative of the Zika virus C, the polynucleotide encoding the Zika virus prM / M or the derivative of the Zika virus prM / M, and the polynucleotide encoding the Zika virus E or the derivative of the Zika virus E are expressed on one or two or more separate nucleic acids.
[0295] 4. The nucleic acid composition according to the preceding embodiment, wherein the polynucleotide encoding the derivative of the Zika virus 5'UTR comprises at least one substitution, at least one deletion and / or at least one insertion compared to the wild-type Zika virus 5'UTR.
[0296] 5. A nucleic acid composition according to the preceding embodiments, wherein the Zika virus 5'UTR or the derivative of the Zika virus 5'UTR comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of Table 1A, Table 1C, Table 1H or Table 2.
[0297] 6. The nucleic acid composition according to the preceding embodiment, wherein the polynucleotide encoding the derivative of the Zika virus 3'UTR comprises at least one substitution, at least one deletion and / or at least one insertion compared to the wild-type Zika virus 3'UTR.
[0298] 7. A nucleic acid composition according to the preceding embodiments, wherein the Zika virus 3'UTR or the derivative of the Zika virus 3'UTR comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of Table 1A, Table 1B, Table 1G or Table 2.
[0299] 8. The nucleic acid composition according to the preceding embodiments, wherein the polynucleotide encoding the derivative of the Zika virus C comprises at least one substitution, at least one deletion and / or at least one insertion compared to wild-type Zika virus C.
[0300] 9. A nucleic acid composition according to the preceding embodiments, wherein the Zika virus C or the derivative of the Zika virus C comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of Table 1A, Table 1D, Table II, Table 2 or Table 3.
[0301] 10. The nucleic acid composition according to the preceding embodiment, wherein the polynucleotide encoding the derivative of the Zika virus prM / M comprises at least one substitution, at least one deletion and / or at least one insertion compared to wild-type Zika virus prM / M.
[0302] 11. A nucleic acid composition according to the preceding embodiments, wherein the Zika virus prM / M or the derivative of the Zika virus prM / M comprises a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of Table 1A, Table 1F or Table 1K.
[0303] 12. A nucleic acid composition according to the preceding embodiments, wherein the polynucleotide encoding the derivative of the Zika virus E comprises at least one substitution, at least one deletion and / or at least one insertion compared to wild-type Zika virus E.
[0304] 13. The nucleic acid composition according to the preceding embodiment, wherein the polynucleotide encoding E is translated into wild-type Zika virus E.
[0305] 14. A nucleic acid composition according to the preceding embodiments, wherein the Zika virus E or the derivative of the Zika virus E comprises a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of Table 1A, Table IE or Table 1J.
[0306] 15. The nucleic acid composition according to the preceding embodiment, wherein the nucleic acid composition comprises the 5' untranslated region (5'UTR) of the Zika virus.
[0307] 16. The nucleic acid composition according to the preceding embodiment, wherein the nucleic acid composition comprises the 3' untranslated region (3'UTR) of the Zika virus.
[0308] 17. A nucleic acid composition according to the preceding embodiments, wherein the nucleic acid composition does not contain a polynucleotide encoding one or more non-structural (NS) proteins, wherein the non-structural (NS) proteins are selected from (i) NS1, (ii) NS2A, (iii) NS2B, (iv) NS3, (v) NS4A, (vi) NS4B, (vii) NS5, or (viii) two or more of (i)-(vii).
[0309] 18. A nucleic acid composition according to the preceding embodiments, wherein the nucleic acid composition further comprises a polynucleotide encoding one or more non-structural (NS) proteins, wherein the non-structural (NS) proteins are selected from (i) NS1, (ii) NS2A, (iii) NS2B, (iv) NS3, (v) NS4A, (vi) NS4B, (vii) NS5, or (viii) two or more of (i)-(vii).
[0310] 19. The nucleic acid composition of embodiment 17 or embodiment 18, wherein the NS1 is Zika virus NS1, the NS2A is Zika virus NS2A, the NS2B is Zika virus NS2B, the NS3 is Zika virus NS3, the NS4A is Zika virus NS4A, the NS4B is Zika virus NS4B, or the NS5 is Zika virus NS5, or any combination of two or more thereof.
[0311] 20. The nucleic acid composition of the preceding embodiment, wherein the components of the nucleic acid composition comprise African Zika virus components, Asian Zika virus components, or Brazilian Zika virus components, or a combination thereof.
[0312] 21. The nucleic acid composition of embodiment 20, wherein the Zika virus is the African MR766 strain.
[0313] 22. The nucleic acid composition according to the preceding embodiment, wherein the exogenous polynucleotide is an antigen or an antigenic epitope thereof.
[0314] 23. A nucleic acid composition according to embodiment 22, wherein the antigen or its antigenic epitope is disease-associated.
[0315] 24. A nucleic acid composition according to embodiment 23, wherein the antigen or its antigenic epitope is from a pathogen.
[0316] 25. The nucleic acid composition of embodiment 24, wherein the pathogen is a virus.
[0317] 26. The nucleic acid composition of embodiment 25, wherein the virus is human SARS coronavirus, influenza A virus, influenza B virus, influenza C virus, Ebola virus, hepatitis B virus, hepatitis C virus, herpes simplex virus, human immunodeficiency virus (HIV), human papillomavirus (HPV-6, HPV-11), measles virus, rabies virus, polio virus or yellow fever virus.
[0318] 27. The nucleic acid composition according to embodiment 24, wherein the pathogen is a bacterium
[0319] 28. A nucleic acid composition according to embodiment 27, wherein the bacteria is Acinetobacter baumannii, Actinomycetemcomitans, Bartonella bacilliformis, Bartonella henselae, Bartonella quinquefasciatus, Bifidobacterium borreliae, Bordetella pertussis, Brucella species, Burkholderia cepacia, Burkholderia pseudomallei, Campylobacter jejuni, Cardiomycobacterium cardiomycota, Campylobacter fetus, Chlamydia pneumoniae, Chlamydia trachomatis, Clostridium difficile, Cyanobacteria, Eikenella corrosus, Enterobacter, Enterococcus faecalis, Escherichia coli, Escherichia coli 0157, tularensis Cissus, Fusobacterium nucleatum, Haemophilus influenzae, Haemophilus sporophilus, Haemophilus ducreyi, Haemophilus parainfluenzae, Helicobacter pylori, Kingella, Klebsiella pneumoniae, Legionella, Legionella pneumophila serotype 1, Leptospira, Morganella morganii, Neisseria gonorrhoeae, Neisseria meningitidis, Proteus mirabilis, Proteus vulgaris, Proteus viscosus, Providencia rettgeri, Providencia alkalinegensis, Providencia stuartii, Pseudomonas aeruginosa, Pseudomonas aeruginosa, Pseudomonas putida, Pseudomonas fluorescens, Pseudomonas acidovorans Mononas, Rickettsia, Salmonella enterica, Salmonella typhi, Salmonella paratyphi A, Salmonella paratyphi B, Salmonella dublin, Salmonella arizona, Salmonella choleraesuis, Serratia marcescens, Shigella dysenteriae, Shigella flexneri, Shigella boydii, Shigella sonnei, Treponema, Stenotrophomonas maltophilia, Vibrio cholerae, Vibrio mimicus), Vibrio alginolyticus, Vibrio holmenii, Vibrio parahaemolyticus, Vibrio vulnificus, Yersinia pestis, Actinomyces, Bacillus anthracis, Bacillus subtilis, Clostridium tetani, Clostridium perfringens, Clostridium botulinum, Clostridium tetani, Corynebacterium diphtheriae, Enterococcus faecalis, Enterococcus faecium, Erysipelothrix rhusiopathiae, Listeria monocytogenes, Mycobacterium leprae, Mycobacterium tuberculosis, Mycoplasma spp., Nocardia spp., Propionibacterium spp., Pseudomonas aeruginosa, Pneumococcus, Staphylococcus aureus, Staphylococcus epidermidis, Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant Staphylococcus aureus (VRSA), Staphylococcus lugdunensis, Staphylococcus saprophyticus, Streptococcus pneumoniae, Streptococcus pyogenes, or Streptococcus mutans.
[0320] 29. The nucleic acid composition of embodiment 24, wherein the pathogen is a fungus, an amoeba, or a parasite.
[0321] 30. The nucleic acid composition of embodiment 29, wherein the fungus, the amoeba or the parasite is an Acanthamoeba species, Chagas' disease, Balamuthia baboons, Babesia divergentis, Babesia diversiformis, Babesia equi, Babesia microti, Babesia duncanii, Balantidium coli, Blastocystis species, Cryptosporidium species, Cyclospora, Dikaryotic Entamoeba fragilis, Diphyllobothrium latum, Leishmania amazonensis, Naegleria fowleri, Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale subsp. coli, Plasmodium malariae, Rhinosporidium sieberii, Sarcocystis hominis, Sarcocystis hominis, Toxoplasma gondii, Trichomonas vaginalis, Trypanosoma brucei, Trypanosoma cruzi and Taenia multiceps.
[0322] 31. A nucleic acid composition according to any one of embodiments 1-30, wherein the exogenous polynucleotide encodes a gene editing tool.
[0323] 32. A nucleic acid composition according to embodiment 31, wherein the gene editing tool is selected from large nuclease-related agents, CRISPR-related agents, TALEN-related agents and zinc finger-related agents.
[0324] 33. A nucleic acid composition according to any one of embodiments 1-30, wherein the exogenous polynucleotide is a small interfering RNA (siRNA), an antisense RNA, a micro RNA (miRNA), a small or short hairpin RNA (shRNA), a guide RNA (gRNA), a clustered regularly interspaced short palindromic repeat RNA (crRNA), a trans-activating clustered regularly interspaced short palindromic repeat RNA (tracrRNA), an immunostimulatory oligonucleotide, an antisense nucleic acid or a ribozyme.
[0325] 34. A nucleic acid composition according to embodiment 33, wherein the exogenous polynucleotide targets β-secretase 1 (BACE1) and / or amyloid precursor protein (APP).
[0326] 35. The nucleic acid composition of any one of embodiments 1-30, wherein the exogenous polynucleotide encodes a polypeptide associated with a genetic disorder.
[0327] 36. A nucleic acid composition according to embodiment 35, wherein the polypeptide is brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), enkephalinase inhibitor (NEP), endothelin-converting enzyme (ECE), cathepsin B (CTSB), apolipoprotein E 2 (APOE2), SH3 and multi-ankyrin repeat domain protein (SHANK), neural rank protein (NRTN), glial cell line-derived neurotrophic factor (GDNF), brain dopamine neurotrophic factor (CDNF), vascular endothelial growth factor A (VEGF-A) or aromatic L-amino acid decarboxylase (AADC).
[0328] 37. The nucleic acid composition of any one of embodiments 1-30, wherein the exogenous polynucleotide encodes a therapeutic or diagnostic agent.
[0329] 38. A nucleic acid composition according to embodiment 37, wherein the therapeutic agent is an antibody-based therapeutic agent, a hormone, a cytokine, an inhibitor or antagonist of an immune checkpoint regulator, an agonist of an immune stimulatory molecule or an immune co-stimulatory molecule.
[0330] 39. The nucleic acid composition of embodiment 38, wherein the inhibitor or antagonist of the immune checkpoint regulator is an anti-PD1 antibody.
[0331] 40. A nucleic acid composition according to embodiment 38, wherein the antibody-based therapeutic agent is an antibody, a functional fragment of an antibody, a chimeric antigen receptor (CAR) or a T cell receptor (TCR).
[0332] 41. The nucleic acid composition of embodiment 38, wherein the cytokines include lymphokines, monokines, polypeptide hormones, growth hormone, parathyroid hormone, thyroxine, insulin, proinsulin, relaxin, prorelaxin, glycoprotein hormones, follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), luteinizing hormone (LH), liver growth factor, fibroblast growth factor, prolactin, placental lactogen, tumor necrosis factor-a and tumor necrosis factor-β, Mullerian inhibitory substance, mouse gonadotropin-related peptide, inhibin, activin, vascular endothelial growth factor, integrin, thrombopoietin (TPO), nerve growth factor, NGF-β, platelet-derived growth factor, transforming growth factor (TGF), TGF-α, TGF-β, insulin-like growth factor-1 and insulin-like growth factor-II, erythropoietin (EPO), osteoinductive factors, interferons (such as interferon-α, interferon-β and interferon-γ), colony stimulating factor (CSF), macrophage-CSF (M-CSF), granulocyte-macrophage-CSF (GM-CSF), granulocyte-CSF (GCSF), interleukin (IL), tumor necrosis factor, TNF-α, TNF-β, LIF or kit ligand (KL), or a combination of two or more thereof.
[0333] 42. A nucleic acid composition according to the preceding embodiments, wherein the exogenous polynucleotide is up to or about 10,000 nucleotides long.
[0334] 43. A nucleic acid composition according to the preceding embodiment, wherein the components of the nucleic acid composition are expressed on one or more separate nucleic acids.
[0335] 44. The nucleic acid composition according to the preceding embodiment, further comprising one or more operably linked expression control elements that confer expression of the nucleic acid composition in vitro or in vivo.
[0336] 45. A nucleic acid composition according to embodiment 44, wherein the expression control element is a promoter that drives the expression of the nucleic acid complex in vitro.
[0337] 46. A nucleic acid composition according to embodiment 45, wherein the promoter is T7, T3, SP6 or any phage promoter.
[0338] 47. A nucleic acid composition according to embodiment 44, wherein the expression control element is a promoter that drives the expression of the nucleic acid complex in the target cell.
[0339] 48. A nucleic acid composition according to embodiment 47, wherein the promoter is CMV, SV40 or any eukaryotic promoter.
[0340] 49. The nucleic acid composition of embodiment 47 or embodiment 48, wherein the target cell is a neuronal or non-neuronal cell, VERO, COS, CHO, C6 / 36, HeLa, HEK or HepG2.
[0341] 50. The nucleic acid composition of embodiment 47 or embodiment 48, wherein the target cell is an oligodendrocyte, a microglia, or an astrocyte.
[0342] 51. A pharmaceutical composition comprising the nucleic acid composition according to the preceding embodiments and a pharmaceutically acceptable salt or derivative thereof.
[0343] 52. A recombinant Zika virus or a Zika virus-like particle, produced by expressing a nucleic acid according to one of embodiments 1-51 in a production cell, wherein the production cell is further infected with a second Zika virus, such that the Zika virus C or the derivative of the Zika virus C, the Zika virus prM / M or the derivative of the Zika virus prM / M, and the Zika virus E or the derivative of the Zika virus E are present in the recombinant Zika virus or the Zika virus-like particle.
[0344] 53. The recombinant Zika virus or Zika virus-like particle of embodiment 52, wherein the second Zika virus is a wild-type Zika virus.
[0345] 54. The recombinant Zika virus or Zika virus-like particle of embodiment 53, wherein the wild-type Zika virus is an African, Asian, and Brazilian strain.
[0346] 55. The recombinant Zika virus or Zika virus-like particle of embodiment 53, wherein the second Zika virus is a modified Zika virus.
[0347] 56. The recombinant Zika virus or Zika virus-like particle of embodiment 55, wherein the modified Zika virus comprises one or more microRNA-based gene silencing mechanisms.
[0348] 57. The recombinant Zika virus or Zika virus-like particle of embodiment 56, wherein the one or more microRNA-based gene silencing mechanisms control viral replication.
[0349] 58. A recombinant Zika virus or Zika virus-like particle, which is produced by expressing a nucleic acid according to embodiments 1-51 in a production cell in the absence of infection by a second Zika virus, wherein the Zika virus C or the derivative of the Zika virus C, the Zika virus prM / M or the derivative of the Zika virus prM / M, and the Zika virus E or the derivative of the Zika virus E are present in the recombinant Zika virus or the Zika virus-like particle.
[0350] 59. The recombinant Zika virus or Zika virus-like particle according to one of embodiments 52-58, wherein the production cell is Vero E6, HEK, HEK 293T, HEK 293TT, FreeStyle TM 293-F cells, HEK-293.2sus or C6 / 36 cells.
[0351] 60. The recombinant Zika virus or Zika virus-like particle of one of embodiments 52-59, wherein the recombinant Zika virus is replication competent.
[0352] 61. The recombinant Zika virus or Zika virus-like particle of one of embodiments 52-60, wherein the recombinant Zika virus is replication-incompetent without reducing vector titer or compromising expression of exogenous polynucleotides.
[0353] 62. The recombinant Zika virus or Zika virus-like particle of one of embodiments 52-61, wherein the recombinant Zika virus or the Zika virus-like particle has reduced insertion mutations.
[0354] 63. The recombinant Zika virus or Zika virus-like particle of one of embodiments 52-62, wherein the recombinant Zika virus or the Zika virus-like particle has a reduced immune response.
[0355] 64. A pharmaceutical composition comprising the recombinant Zika virus or Zika virus-like particle according to one of embodiments 52-63, and a pharmaceutically acceptable salt or derivative thereof.
[0356] 65. A method of delivering an exogenous polynucleotide to a target cell, the method comprising administering to the target cell a recombinant Zika virus or Zika virus-like particle according to one of embodiments 52-64 comprising the exogenous polynucleotide.
[0357] 66. A method according to embodiment 65, wherein the target cell is a neuron or a non-neuronal cell.
[0358] 67. A method according to embodiment 66, wherein the neurons are oligodendrocytes, microglia or astrocytes.
[0359] 68. A method according to embodiment 66, wherein the non-neuronal cells are prostate epithelial cells, urothelial cells, supporting cells, Leydig cells, spermatogonia or retinal cells.
[0360] 69. The method according to one of embodiments 65-68, wherein the method is performed in vitro, ex vivo or in vivo.
[0361] 70. The method of one of embodiments 65-69, wherein the target cell transiently expresses the exogenous polynucleotide after delivery.
[0362] 71. The method of one of embodiments 65-69, wherein the target cell continuously expresses the exogenous polynucleotide after delivery.
[0363] 72. A method for treating Alzheimer's disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a recombinant Zika virus or Zika virus-like particle according to one of embodiments 52-71, wherein the recombinant Zika virus or Zika virus-like particle comprises a polynucleotide encoding brain-derived neurotrophic factor (BDNF).
[0364] 73. A method for treating autism in a subject in need thereof, the method comprising administering to the subject an effective amount of a recombinant Zika virus or Zika virus-like particle according to one of embodiments 52-71, wherein the recombinant Zika virus or Zika virus-like particle comprises a polynucleotide encoding an SH3 and multi-ankyrin repeat domain protein (SHANK).
[0365] 74. A method for treating Parkinson's disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a recombinant Zika virus or Zika virus-like particle according to one of embodiments 52-71, wherein the recombinant Zika virus or Zika virus-like particle comprises a polynucleotide encoding an aromatic L-amino acid decarboxylase (AADC).
[0366] 75. The method of one of embodiments 65-74, wherein the administration is performed via systemic delivery.
[0367] 76. The method according to one of embodiments 65-74, wherein the administration is performed intravenously and / or intratumorally.
[0368] 77. The method of one of embodiments 65-76, wherein the administration targets the intraventricular, cisterna magna, subpial and / or intrathecal cerebrospinal fluid.
[0369] 78. The method of one of embodiments 65-77, wherein the administration is not performed within the brain parenchyma.
[0370] 79. A nucleic acid composition comprising (i) a polynucleotide encoding a ribozyme; (ii) a 5' untranslated region (UTR) of a Zika virus; (iii) a 3'UTR of the Zika virus; and (iv) a polynucleotide exogenous to the Zika virus;
[0371] Optionally, wherein the polynucleotide encoding the ribozyme is located before the 5'UTR or after the 3'UTR;
[0372] Further optionally, wherein the polynucleotide encoding a ribozyme is a first polynucleotide encoding a ribozyme, and the nucleic acid composition comprises a second polynucleotide encoding a ribozyme, and the first polynucleotide is located before the 5'UTR, and the second polynucleotide is located after the 3'UTR.
[0373] 80. The nucleic acid composition of embodiment 79, wherein the ribozyme is a hammerhead ribozyme or a hepatitis delta virus (HDV) ribozyme.
[0374] 81. The nucleic acid composition of embodiment 79 or embodiment 80, comprising a polynucleotide encoding a second ribozyme.
[0375] 82. The nucleic acid composition of embodiment 81, wherein the second ribozyme is a hammerhead ribozyme or a hepatitis delta virus (HDV) ribozyme.
[0376] 83. The nucleic acid composition of embodiment 81 or embodiment 82, wherein the polynucleotide encoding the ribozyme encodes a hammerhead ribozyme and the polynucleotide encoding the second ribozyme encodes an HDV ribozyme.
[0377] 84. The nucleic acid composition of any one of embodiments 79-83, comprising a C-portion (e.g., a polynucleotide encoding a truncation of C, such as less than or about 30, 25, 20, 15, 10, or 5 amino acids of C).
[0378] 85. The nucleic acid composition of any one of embodiments 79-84, wherein the Zika virus is an African Zika virus, an Asian Zika virus, a Brazilian Zika virus component, or a combination of one or both thereof.
[0379] 86. The nucleic acid composition of any one of embodiments 79-85, wherein the Zika virus is the African MR766 strain.
[0380] 87. A nucleic acid composition according to any one of embodiments 79-86, wherein the exogenous polynucleotide is an antigen or an antigenic epitope thereof.
[0381] 88. A nucleic acid composition according to embodiment 87, wherein the antigen or its antigenic epitope is disease-associated.
[0382] 89. A nucleic acid composition according to embodiment 88, wherein the antigen or its antigenic epitope is from a pathogen.
[0383] 90. The nucleic acid composition of embodiment 89, wherein the pathogen is a virus.
[0384] 91. The nucleic acid composition of embodiment 90, wherein the virus is human SARS coronavirus, influenza A virus, influenza B virus, influenza C virus, Ebola virus, hepatitis B virus, hepatitis C virus, herpes simplex virus, human immunodeficiency virus (HIV), human papillomavirus (HPV-6, HPV-11), measles virus, rabies virus, polio virus or yellow fever virus.
[0385] 92. The nucleic acid composition of embodiment 89, wherein the pathogen is a bacterium.
[0386] 93. A nucleic acid composition according to embodiment 92, wherein the bacteria is Acinetobacter baumannii, Actinomycetemcomitans, Bartonella bacilliformis, Bartonella henselae, Bartonella quinquefasciatus, Bifidobacterium borreliae, Bordetella pertussis, Brucella species, Burkholderia cepacia, Burkholderia pseudomallei, Campylobacter jejuni, Cardiomycobacterium cardiomycota, Campylobacter fetus, Chlamydia pneumoniae, Chlamydia trachomatis, Clostridium difficile, Cyanobacteria, Eikenella corrosus, Enterobacter, Enterococcus faecalis, Escherichia coli, Escherichia coli 0157, tularensis Cissus, Fusobacterium nucleatum, Haemophilus influenzae, Haemophilus sporophilus, Haemophilus ducreyi, Haemophilus parainfluenzae, Helicobacter pylori, Kingella, Klebsiella pneumoniae, Legionella, Legionella pneumophila serotype 1, Leptospira, Morganella morganii, Neisseria gonorrhoeae, Neisseria meningitidis, Proteus mirabilis, Proteus vulgaris, Proteus viscosus, Providencia rettgeri, Providencia alkalinegensis, Providencia stuartii, Pseudomonas aeruginosa, Pseudomonas aeruginosa, Pseudomonas putida, Pseudomonas fluorescens, Pseudomonas acidovorans Mononas, Rickettsia, Salmonella enterica, Salmonella typhi, Salmonella paratyphi A, Salmonella paratyphi B, Salmonella dublin, Salmonella arizona, Salmonella choleraesuis, Serratia marcescens, Shigella dysenteriae, Shigella flexneri, Shigella boydii, Shigella sonnei, Treponema, Stenotrophomonas maltophilia, Vibrio cholerae, Vibrio mimicus), Vibrio alginolyticus, Vibrio holmenii, Vibrio parahaemolyticus, Vibrio vulnificus, Yersinia pestis, Actinomyces, Bacillus anthracis, Bacillus subtilis, Clostridium tetani, Clostridium perfringens, Clostridium botulinum, Clostridium tetani, Corynebacterium diphtheriae, Enterococcus faecalis, Enterococcus faecium, Erysipelothrix rhusiopathiae, Listeria monocytogenes, Mycobacterium leprae, Mycobacterium tuberculosis, Mycoplasma spp., Nocardia spp., Propionibacterium spp., Pseudomonas aeruginosa, Pneumococcus, Staphylococcus aureus, Staphylococcus epidermidis, Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant Staphylococcus aureus (VRSA), Staphylococcus lugdunensis, Staphylococcus saprophyticus, Streptococcus pneumoniae, Streptococcus pyogenes, or Streptococcus mutans.
[0387] 94. The nucleic acid composition of embodiment 89, wherein the pathogen is a fungus, an amoeba, or a parasite.
[0388] 95. The nucleic acid composition of embodiment 94, wherein the fungus, the amoeba, or the parasite is an Acanthamoeba species, Chagas' disease, Balamuthia baboons, Babesia divergentis, Babesia diversiformis, Babesia equi, Babesia microti, Babesia duncanii, Balantidium coli, Blastocystis species, Cryptosporidium species, Cyclospora, Dikaryotic Entamoeba fragilis, Diphyllobothrium latum, Leishmania amazonensis, Naegleria fowleri, Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale subsp. coli, Plasmodium malariae, Rhinosporidium sieberii, Sarcocystis hominis, Sarcocystis hominis, Toxoplasma gondii, Trichomonas vaginalis, Trypanosoma brucei, Trypanosoma cruzi, and Taenia multiceps.
[0389] 96. A nucleic acid composition according to any one of embodiments 79-95, wherein the exogenous polynucleotide encodes a gene editing tool.
[0390] 97. A nucleic acid composition according to embodiment 96, wherein the gene editing tool is selected from large nuclease-related agents, CRISPR-related agents, TALEN-related agents and zinc finger-related agents.
[0391] 98. A nucleic acid composition according to any one of embodiments 79-97, wherein the exogenous polynucleotide is a small interfering RNA (siRNA), an antisense RNA, a micro RNA (miRNA), a small or short hairpin RNA (shRNA), a guide RNA (gRNA), a clustered regularly interspaced short palindromic repeat RNA (crRNA), a trans-activating clustered regularly interspaced short palindromic repeat RNA (tracrRNA), an immunostimulatory oligonucleotide, an antisense nucleic acid or a ribozyme.
[0392] 99. A nucleic acid composition according to embodiment 98, wherein the exogenous polynucleotide targets BACE1 or APP.
[0393] 100. The nucleic acid composition of any one of embodiments 79-99, wherein the exogenous polynucleotide encodes a polypeptide associated with a genetic disorder.
[0394] 101. A nucleic acid composition according to embodiment 100, wherein the polypeptide is brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), enkephalinase inhibitor (NEP), endothelin-converting enzyme (ECE), cathepsin B (CTSB), apolipoprotein E 2 (APOE2), SH3 and multi-ankyrin repeat domain protein (SHANK), neural rank protein (NRTN), glial cell line-derived neurotrophic factor (GDNF), brain dopamine neurotrophic factor (CDNF), vascular endothelial growth factor A (VEGF-A) or aromatic L-amino acid decarboxylase (AADC).
[0395] 102. The nucleic acid composition of any one of embodiments 79-101, wherein the exogenous polynucleotide encodes a therapeutic or diagnostic agent.
[0396] 103. A nucleic acid composition according to embodiment 102, wherein the therapeutic agent is an antibody-based therapeutic agent, a hormone, a cytokine, an inhibitor or antagonist of an immune checkpoint regulator, an agonist of an immune stimulatory molecule or an immune co-stimulatory molecule.
[0397] 104. A nucleic acid composition according to embodiment 103, wherein the inhibitor or antagonist of the immune checkpoint regulator is an anti-PD1 antibody.
[0398] 105. A nucleic acid composition according to embodiment 103, wherein the antibody-based therapeutic agent is an antibody, a functional fragment of an antibody, a chimeric antigen receptor (CAR) or a T cell receptor (TCR).
[0399] 106. A nucleic acid composition according to embodiment 103, wherein the cytokines include lymphokines, monokines, polypeptide hormones, growth hormone, parathyroid hormone, thyroxine, insulin, proinsulin, relaxin, prorelaxin, glycoprotein hormones, follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), luteinizing hormone (LH), liver growth factor, fibroblast growth factor, prolactin, placental lactogen, tumor necrosis factor-a and tumor necrosis factor-β, Mullerian inhibitory substance, mouse gonadotropin-related peptide, inhibin, activin, vascular endothelial growth factor, integrin, thrombopoietin (TPO), nerve growth factor , NGF-β, platelet-derived growth factor, transforming growth factor (TGF), TGF-a, TGF-β, insulin-like growth factor-1 and insulin-like growth factor-II, erythropoietin (EPO), osteoinductive factors, interferons (such as interferon-a, interferon-β and interferon-γ), colony stimulating factor (CSF), macrophage-CSF (M-CSF), granulocyte-macrophage-CSF (GM-CSF), granulocyte-CSF (GCSF), interleukin (IL), tumor necrosis factor, TNF-a, TNF-β, LIF or kit ligand (KL), or a combination of two or more thereof.
[0400] 107. The nucleic acid composition of one of embodiments 79-106, wherein the exogenous polynucleotide is up to or about 10,000 nucleotides in length.
[0401] 108. The nucleic acid composition of one of embodiments 79-107, comprising one or more operably linked expression control elements that confer expression of the nucleic acid composition in vitro.
[0402] 109. A nucleic acid composition according to embodiment 108, wherein the expression control element is a promoter that drives the expression of the nucleic acid complex in vitro.
[0403] 110. A nucleic acid composition according to embodiment 109, wherein the promoter is T7, T3, SP6 or any phage promoter.
[0404] 111. A pharmaceutical composition comprising the nucleic acid composition according to one of embodiments 79-110 and a pharmaceutically acceptable salt or derivative thereof.
[0405] 112. A method for delivering an exogenous polynucleotide to a target cell, the method comprising administering to the target cell a compound comprising the exogenous polynucleotide produced by a nucleic acid composition according to one of embodiments 79-111; optionally, wherein the compound is tropic for the target cell; further optionally, wherein the target cell is a cell of the central nervous system; further optionally, wherein the target cell is present in a subject, and administering to the target cell comprises administering the compound to the subject; further optionally, wherein the subject is a human or a non-human animal.
[0406] 113. A method according to embodiment 112, wherein the compound is produced by encapsulating transcripts produced by the nucleic acid composition with a lipid-based agent.
[0407] 114. A method according to embodiment 113, wherein the transcript is uncapped.
[0408] 115. A method according to embodiment 113 or embodiment 114, wherein the transcript is produced by transcribing the nucleic acid composition in vitro.
[0409] 116. A method according to any one of embodiments 112-115, wherein the lipid-based agent is a lipofectamine-related agent, a liposome, or a lipid nanoparticle.
[0410] 117. A method of triggering or enhancing an immune response in a subject, the method comprising administering to the subject an effective amount of a compound produced by a nucleic acid composition according to one of embodiments 79-110 or a composition according to embodiment 11, the composition comprising an antigen or an antigenic epitope thereof; optionally, wherein the subject is a human or a non-human animal.
[0411] 118. A method according to embodiment 117, wherein the compound is produced by encapsulating transcripts produced by the nucleic acid composition with a lipid-based agent.
[0412] 119. A method according to embodiment 118, wherein the transcript is uncapped.
[0413] 120. A method according to embodiment 188 or embodiment 119, wherein the transcript is produced by transcribing the nucleic acid composition in vitro.
[0414] 121. A method according to any one of embodiments 117-120, wherein the lipid-based agent is a lipofectamine-related agent, a liposome, or a lipid nanoparticle.
[0415] 122. The method of any one of embodiments 112-121, wherein the administration is performed intramuscularly.
[0416] 123. A method according to any one of embodiments 112-122, wherein the antigen or its antigenic epitope is from a pathogen.
[0417] 124. The method of embodiment 123, wherein the pathogen is a virus.
[0418] 125. The method of embodiment 124, wherein the virus is human SARS coronavirus, influenza A virus, influenza B virus, influenza C virus, Ebola virus, hepatitis B virus, hepatitis C virus, herpes simplex virus, human immunodeficiency virus (HIV), human papillomavirus (HPV-6, HPV-11), measles virus, rabies virus, polio virus or yellow fever virus.
[0419] 126. The method of embodiment 123, wherein the pathogen is a bacterium.
[0420] 127. The method according to embodiment 126, wherein the bacteria is Acinetobacter baumannii, Actinomycetemcomitans, Bartonella bacilliformis, Bartonella henselae, Bartonella quinquefasciatus, Bifidobacterium borreliae, Bordetella pertussis, Brucella species, Burkholderia cepacia, Burkholderia pseudomallei, Campylobacter jejuni, Cardiomycobacterium cardiomycota, Campylobacter fetus, Chlamydia pneumoniae, Chlamydia trachomatis, Clostridium difficile, Cyanobacteria, Eikenella corrosus, Enterobacter, Enterococcus faecalis, Escherichia coli, Escherichia coli 0157, tularensis, Cissus, Fusobacterium nucleatum, Haemophilus influenzae, Haemophilus sporophilus, Haemophilus ducreyi, Haemophilus parainfluenzae, Helicobacter pylori, Kingella, Klebsiella pneumoniae, Legionella, Legionella pneumophila serotype 1, Leptospira, Morganella morganii, Neisseria gonorrhoeae, Neisseria meningitidis, Proteus mirabilis, Proteus vulgaris, Proteus viscosus, Providencia rettgeri, Providencia alkalinegensis, Providencia stuartii, Pseudomonas aeruginosa, Pseudomonas aeruginosa, Pseudomonas putida, Pseudomonas fluorescens, Pseudomonas acidovorans Mononas, Rickettsia, Salmonella enterica, Salmonella typhi, Salmonella paratyphi A, Salmonella paratyphi B, Salmonella dublin, Salmonella arizona, Salmonella choleraesuis, Serratia marcescens, Shigella dysenteriae, Shigella flexneri, Shigella boydii, Shigella sonnei, Treponema, Stenotrophomonas maltophilia, Vibrio cholerae, Vibrio mimicus), Vibrio alginolyticus, Vibrio holmenii, Vibrio parahaemolyticus, Vibrio vulnificus, Yersinia pestis, Actinomyces, Bacillus anthracis, Bacillus subtilis, Clostridium tetani, Clostridium perfringens, Clostridium botulinum, Clostridium tetani, Corynebacterium diphtheriae, Enterococcus faecalis, Enterococcus faecium, Erysipelothrix rhusiopathiae, Listeria monocytogenes, Mycobacterium leprae, Mycobacterium tuberculosis, Mycoplasma spp., Nocardia spp., Propionibacterium spp., Pseudomonas aeruginosa, Pneumococcus, Staphylococcus aureus, Staphylococcus epidermidis, Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant Staphylococcus aureus (VRSA), Staphylococcus lugdunensis, Staphylococcus saprophyticus, Streptococcus pneumoniae, Streptococcus pyogenes, or Streptococcus mutans.
[0421] 128. The method of embodiment 123, wherein the pathogen is a fungus, an amoeba, or a parasite.
[0422] 129. The method of embodiment 128, wherein the fungus, the ameba, or the parasite is Acanthamoeba sp., Chagas' disease, Balamuthia baboons, Babesia divergentis, Babesia dimorpha, Babesia equi, Babesia microti, Babesia duncanii, Balantidium coli, Blastocystis sp., Cryptosporidium sp., Cyclospora, Dienucleate amoeba fragilis, Diphyllobothrium latum, Leishmania amazonensis, Naegleria fowleri, Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale subsp. coli, Plasmodium malariae, Rhinosporidium sieberii, Sarcocystis hominis, Sarcocystis hominis, Toxoplasma gondii, Trichomonas vaginalis, Trypanosoma brucei, Trypanosoma cruzi, and Taenia multiceps.
[0423] Table 1A Non-limiting exemplary Zika sequences
[0424]
[0425] Table 1B Non-limiting exemplary Zika 3'UTR sequences
[0426]
[0427]
[0428]
[0429]
[0430]
[0431]
[0432]
[0433]
[0434]
[0435] Table 1C Non-limiting exemplary Zika 5'UTR sequences
[0436]
[0437]
[0438]
[0439]
[0440]
[0441]
[0442]
[0443]
[0444]
[0445] Table 1D Non-limiting exemplary Zika capsid (C) sequences
[0446]
[0447]
[0448]
[0449]
[0450]
[0451]
[0452]
[0453] Table 1E Non-limiting exemplary envelope protein (E) sequences
[0454]
[0455]
[0456]
[0457]
[0458]
[0459]
[0460]
[0461]
[0462]
[0463]
[0464]
[0465] Table 1F Non-limiting exemplary Zika protein M sequences
[0466]
[0467]
[0468]
[0469]
[0470]
[0471]
[0472]
[0473]
[0474]
[0475]
[0476]
[0477]
[0478]
[0479]
[0480]
[0481]
[0482] Table 1G Non-limiting exemplary Zika 3'UTR sequences by accession number
[0483]
[0484]
[0485]
[0486]
[0487]
[0488]
[0489]
[0490]
[0491] Table 1H Non-limiting exemplary Zika 5'UTR sequences by accession number
[0492]
[0493]
[0494]
[0495]
[0496]
[0497]
[0498]
[0499]
[0500] Table II Non-limiting exemplary Zika capsid (C) sequences by accession number
[0501]
[0502]
[0503]
[0504]
[0505]
[0506]
[0507]
[0508] Table 1J Non-limiting exemplary Zika protein E sequences by accession number
[0509]
[0510]
[0511]
[0512]
[0513]
[0514]
[0515]
[0516]
[0517]
[0518]
[0519]
[0520] Table 1K Non-limiting exemplary Zika protein M sequences by accession number
[0521]
[0522]
[0523]
[0524]
[0525]
[0526]
[0527]
[0528]
[0529]
[0530]
[0531] Example
[0532] Example 1: In vitro transcription and RNA transfection of constructs carrying Nluc and eGFP constructs in Vero cells
[0533] The plasmid carrying the sequences of RNA polymerase promoter, hammerhead ribozyme, 5'UTR, C-part, 3'UTR, HDV ribozyme and encoding GFP and Nluc luciferase is constructed as follows Figure 5 Design shown. See also Table 2.
[0534] RNA generated by in vitro transcription of the linearized plasmid was transfected into Vero cells. TM MessengerMAX TM (Thermo Scientific TM Catalog No. LMRNA001) was used for transient transfection, and fresh medium was added to the cells 24 hours later.
[0535] After 48 hours, the transfected Vero cells were imaged in vivo. TM ) to detect GFP signal. Figure 3 As shown, after expressing GFP via cytoplasmic RNA replicon transfection, the GFP signal was strong in positively transfected Vero cells.
[0536] In another experiment, Nluc luciferase activity was determined after transfection of uncapped RNA.
[0537] Plasmids with Nluc activity were transcribed in vitro. In vitro transcription was performed using the kit MEGAscript (Catalog No. AM1330, Life Technologies) according to the user manual. In brief, 1 μg of linearized plasmid was used and the reaction was continued for 2 hours. After precipitation with lithium chloride and isopropanol, the RNA was resuspended in water and stored at -80°C.
[0538] Lipofectamine TM MessengerMAX TM (ThermoScientific TM The transcripts were pretreated with Lipofectamine TM MessengerMAX TM The complexes were incubated with Vero cells (obtained from ATCC), and after 24 hours, fresh medium was added to the cells.
[0539] The supernatant and pellet of the transfected cells were resuspended in 1 volume of NanoGlo detection reagent (Promega) previously diluted 50-fold in water. Luminescence was quantified for 0.5 seconds in a GloMax luminometer (Promega). Figure 6 D and Figure 6 As shown in E, high Nluc activity was observed in both cell lysates and supernatants of Vero cells, demonstrating that uncapped RNAs with ZIKV 5'UTR and 3'UTR are recognized by the human translation machinery.
[0540] Table 2. Figure 5 sequence.
[0541]
[0542]
[0543] Example 2: Construction of recombinant Zika virus
[0544] The constructs carrying the eukaryotic promoter, hammerhead ribozyme, 5'UTR, C-part, 3'UTR, sequences of HDV ribozyme and plasmids encoding GFP and Nluc luciferase were designed.
[0545] Vero cells were obtained from ATCC and cultured in DMEM high medium. After reaching 80% confluence, DNA linear plasmids were transfected. Lipofectamine P3000 (Thermo Scientific) TM Catalog number L3000015) was transfected. After 24 hours, fresh medium was added to the cells. In order to select for stable expression of pREP, zeomycin [1 mg / mL] was added to the culture medium. Thus, Vero cells expressing the pREP construct (Vero_pREP) were obtained (see Figure 4A ).
[0546] like Figure 4B As shown, Vero_pREP was infected with wild-type Zika virus from the Brazilian strain, which was isolated from a clinical case in Brazil and provided by the Evandro Chagas Institute (Belém, Pará, Brazil). Vero_pREP cells were infected at a virus concentration of MOI 2. After an incubation period of 30 minutes, the culture infection buffer was replaced with fresh culture medium.
[0547] After 24, 48 and 72 hours, recombinant Zika virus (ZIKVV) containing the viral vector was produced from the transfected Vero_pREP and collected from the culture medium.
[0548] The culture supernatant containing ZIKVV was stored at -80°C.
[0549] Separately, culture the ATCC-derived TM The medulloblastoma tumor cell line Daoy was obtained.
[0550] Medulloblastoma tumor cell lines were infected with viral vectors generated from transfected Vero-pREP (see Figure 4C ).
[0551] After 24 hours, infected medulloblastoma tumor cell line (Daoy) was imaged in vivo. The images were acquired using a fluorescence microscope (EVOS M5000 Imaging System, ThermoFisher TM ) to detect GFP signal. Figure 4D As shown, GFP fluorescence was observed in medulloblastoma cell lines after infection with recombinant Zika virus.
[0552] Figure 4E Shown is a medulloblastoma cell line 48 hours after infection with wild-type Brazilian Zika virus. Figure 4F Medulloblastoma cell lines infected with recombinant Zika virus for 48 hours are shown with low numbers of adherent cells and cell viability, showing the enhanced oncolytic effect of recombinant Zika virus when compared to wild-type Zika virus.
[0553] In another experiment, in vitro transcription and transfection in Vero cells Figure 5 The carrier ( Figure 7 Step 1), followed by ZIKV infection ( Figure 7 Step 2). 120 hours after ZIKV infection, the culture supernatant containing the viral vector (ZIKVV) produced by Vero cells was collected and concentrated by centrifugation with PEG. To test the function of the viral vector, the concentrated supernatant was contacted with target cells (Vero and Daoy cell lines) to confirm Nanoluc delivery by ZIKVV ( Figure 7 Step 3). Figure 7 The graph in step 4 of shows Nanoluc quantification in Daoy and Vero cells after contact with viral vectors (pREP+ZIKV) compared to pREP control (pREP transfection only) and ZIKV (ZIKV infection only). Higher levels of NanoLuc expression were shown in the case of pREP+ZIKV when compared to the control group. These results indicate that ZIKVV delivers NanoLuc to target cells and confirms expression of the reporter gene in target cells.
[0554] Example 3: Expression of Nluc or eGFP after infection with recombinant Zika virus
[0555] Medulloblastoma tumor cell lines were infected with recombinant Zika virus prepared similarly to Example 2. Survival and in vitro transduction rates were measured. Briefly, medulloblastoma cell lines were cultured in 96-well plates and infected with recombinant Zika virus at an MOI of 1. Cell viability and Nluc expression were measured using 2.0 Cell viability assay (Promega - Catalog No. G9242) and Luciferase assay (Promega - Cat. No. N1110) was measured according to the manufacturer's instructions.
[0556] Separately, the whole genome of the infected cell lines was sequenced and the likelihood of insertional mutagenesis was assessed.
[0557] Similarly, recombinant Zika virus was injected into wild-type BalBc mice. Body weight, activity, inflammation levels near the injection site and systemic inflammatory markers in the blood, possible morbidity, were monitored over several weeks after injection. In vivo transduction rate and effectiveness across the blood-brain barrier were also assessed.
[0558] Primary T cells were collected from peripheral blood mononuclear cells (PBMCs) of healthy donor patients. After transduction of primary T cells with recombinant Zika virus prepared similarly to Example 1 or 2, the survival rate and in vitro transduction rate of primary T cells after infection were measured.
[0559] Example 4: Treatment of Alzheimer's disease with recombinant Zika virus or Zika virus-like particles
[0560] Establishment of Alzheimer's disease mouse model.
[0561] The recombinant Zika virus or Zika virus-like particles carrying a polynucleotide encoding brain-derived neurotrophic factor (BDNF) are prepared similarly to Example 1 or 2.
[0562] Morris water maze test and other behavioral tests on memory formation and retention were tested on BDNF-treated and mock-treated mice one month after infection with different titers of recombinant Zika virus or Zika virus-like particles.
[0563] Example 5: Quantification of RNA from generated viral vectors
[0564] RNA quantification was performed from different viral vector batches produced.
[0565] RT-PCR was performed using specific primers for the ZIKV genome (gene ZIKV) and pREP (gene pREP) to compare the RNA amounts of the ZIKV genome and pREP after pREP transfection and ZIKV infection in Vero cells ( Figure 7 , steps 1-3). When pREP RNA copies were compared to a batch of ZIKV genomic RNA copies produced after infection with ZIKV at MOI 1, the difference was ten-fold greater ( Figure 8 The second batch prepared after infection with ZIKV at MOI 0.1 showed a pREPRNA copy number comparable to the ZIKV genome copy number ( Figure 8 ). These findings suggest that at high MOI, the pREP gene copy number of ZIKVV is 10-fold higher than that of the ZIKV genome, where the pREP gene is amplified by the viral machinery.
[0566] Example 5: Viral vector exotropy
[0567] The in vitro tropism of ZIKVV (ZIKV genome and pREP RNA) was assessed. Entry of ZIKVV, ZIKV wild-type, or control (pREP mRNA) was tested in cells sensitive to wild-type ZIKV (hCMEC and Daoy) and insensitive to wild-type ZIKV (HCT-8). Cell lines were combined with wild-type virus (ZIKV wild-type), viral vector (ZIKVV), and pREP mRNA (control). If the viral vector retains the ability to enter the cell line like wild-type ZIKV, mRNA carrying a reporter gene encoding the enzyme NanoLuc luciferase will be delivered and translated, detected by a luminescence assay. ZIKVV can deliver genes of interest to cell lines (including the insensitive HCT-8 cell line), indicating a higher spectrum of viral vector action, not limited to neural and stem-like cells that are sensitive to wild-type ZIKV ( Fig. 9 ).
[0568] Example 6: Evaluation of ZIKV for Delivery of Various Genes of Interest
[0569] mRNA prepared from Zika vectors with various genes of interest were evaluated. Exemplary vectors are Fig.10 (pREP-Luc / Gal) and Fig.11 (pREP-Spike), where Fig.10 The genes in the gene are polycistronic luciferase and β-galactosidase, and Fig.11 The gene in encodes the SARS-CoV-2 spike protein. Vero cells were transfected with pREP-Luc / Gal and the expression of two reporter genes showed the ability of the pREP construct to deliver and promote the expression of multiple genes with up to 6Kb ( Fig.12 In addition, the SARS-CoV-2 spike coding sequence was inserted into the pREP plasmid to evaluate the intensity of expression by ELISA ( Fig.13 ), indicating that the pREP construct can deliver and promote the expression of other genes of interest and confirming the use of pREP mRNA as a vaccine product.
[0570] Example 7: Evaluation of Zika capsid coding sequences
[0571] Five constructs using plasmids ( Figures 14A-14E ) to perform pREP( Figure 5 ) Evaluation of the Zika capsid sequence required for encapsulation, the construct carries the sequence of a eukaryotic promoter, RNA polymerase promoter, hammerhead ribozyme, 5'UTR, C-part (15bp, 30bp, 45bp, 60bp or 75bp), 3'UTR, HDV ribozyme and encodes GFP and Nluc luciferase. For C-part sequences, see Tables 2 and 3 below.
[0572] The vector was transcribed in vitro using the kit MEGAscript (Cat. No. AM1330, Life Technologies) according to the user manual.
[0573] Vero cells were obtained from ATCC and cultured in DMEM high medium. After reaching 80% confluence, RNA ( Figure 14A-14E ) and DNA( Fig.14A and Fig. 14C ) plasmid. Lipofectamine P3000 (Thermo Scientific) was used under the manufacturer's instructions. TM Catalog No. L3000015) for DNA transfection and Lipofectamine TM MessengerMAX TM (Thermo Scientific TM RNA transfection was performed using RNAi (Catalog No. LMRNA001).
[0574] After 24 hours, Vero cells were infected with wild-type Zika virus. Vero cells were infected at a virus concentration of MOI 0.01. After a 30-minute incubation period, the culture infection buffer was replaced with fresh culture medium.
[0575] After 120 hours of ZIKV infection, the culture supernatant containing the viral vector (ZIKVV) produced by Vero cells was collected and concentrated by centrifugation with PEG.
[0576] RNA quantification from different viral vectors produced ( Figures 14A-14E ).
[0577] RT-PCR was performed using specific primers for the ZIKV genome (ZIKV gene) and pREP (pREP gene) to detect the RNA amounts of the ZIKV genome and pREP after pREP transfection and ZIKV infection in Vero cells. pREP RNA copies were quantified from all pREPs with capsid sequences of different sizes ( Figure 16A-16B ). Fig.16A pREP RNA encapsulation in all tested plasmids is shown (with C-parts of 15 bp, 30 bp, 45 bp, 60 bp and 75 bp). The encapsulation of pREP RNA was higher in plasmids with C-parts (with 15 bp, 30 bp, 45 bp and 60 bp), indicating that ZIKVV carrying pREP RNA with capsid (with 20 or less amino acids) was more efficiently encapsulated into viral vectors. Fig. 16BIt was shown that encapsulation derived from DNA transfection is highly efficient and that the plasmid with the C-part 45 bp had a higher amount of pREP RNA.
[0578] To test whether viral vectors encapsidate pREP with capsid sequences of different sizes ( Figure 14A-14E ), and the concentrated supernatant was contacted with Vero cell line to confirm Nanoluc delivery by ZIKVV ( Figure 7 Step 3). ( Fig.17A and Fig. 17B ) shows Nanoluc quantification in Vero cells after contact with viral vectors carrying 5, 10, 15, 20, and 25 amino acids (pREP+ZIKV) derived from RNA ( Fig.17A ) and DNA( Fig. 17B ) transfection. Compared with the control group, higher levels of NanoLuc expression were shown in viral vectors of all capsid sequence sizes. These results show that ZIKVV is able to encapsulate pREPRNA with C-parts (15bp, 30bp, 45bp, 60bp and 75bp) and deliver NanoLuc, which is confirmed by the expression of reporter genes in target cells.
[0579] Table 3: For pREP( Figure 14A-14E ) encapsulated Zika capsid sequence.
[0580]
[0581] Example 8: In vivo ZIKVV biodistribution and tropism
[0582] The present technology features the potential to generate viral vectors with CNS and ocular tropism. To track the in vivo biodistribution and tropism of ZIKVV, a bioluminescent imaging system was used based on the Nanoluc reporter gene inserted into the gene of interest in the vector. ZIKVV (ZIKVV) was systemically administered to 3-week-old Balb / C male mice by intraperitoneal injection of ZIKVV produced as in Example 2 and carrying pREP RNA. Figure 5). 50ul of 10-fold diluted ZIKVV was administered, for a total of 10^4 particles. For bioluminescent imaging, mice were administered 50ul of Nanoluc substrate (Promega-50-fold dilution) by intraperitoneal administration immediately before image acquisition by IVIS Spectrum equipment (Perkin-Elmer). Strong signals of Nanoluc were observed in the brain and eye regions 48 hours after injection of ZIKVV in mice. This result confirms the in vivo tropism of ZIKVV to the eyes and brain, and that after systemic vector administration, the vector selectively delivers and transduces the gene of interest on these organs.
[0583] The foregoing only illustrates the principle of the present disclosure. It should be understood that those skilled in the art will be able to envision various arrangements, although these arrangements are not explicitly described or shown herein, they embody the principle of the present invention and are included in its spirit and scope. In addition, all embodiments and conditional language cited herein are mainly intended to help readers understand the principle of the present disclosure and the conception of promoting technology provided by the inventor, and should be interpreted as not limiting such particularly cited embodiments and conditions. In addition, all statements citing the principles, aspects and embodiments of the present invention and its specific embodiments herein are intended to cover their structural equivalents and functional equivalents. In addition, it is intended that such equivalents include currently known equivalents and equivalents developed in the future, that is, regardless of the structure, any element developed to perform the same function. Therefore, the scope of the present disclosure is not intended to be limited to the exemplary embodiments shown and described herein. On the contrary, the scope and spirit of the present disclosure are embodied by the appended claims.
Claims
1. A method for delivering a polynucleotide to a target cell in a subject, the method comprising administering to the subject a Zika virus or a Zika virus-like particle comprising the polynucleotide, wherein the polynucleotide is not a Zika virus polynucleotide and the target cell is a cell of the central nervous system.
2. A method of delivering a polynucleotide to a subject, the method comprising administering to the subject a Zika virus or a Zika virus-like particle comprising the polynucleotide, wherein the polynucleotide is not a Zika virus polynucleotide and the Zika virus or Zika virus-like particle does not comprise a replicating Zika virus.
3. A method of delivering a polynucleotide to a subject, the method comprising administering to the subject a Zika virus or Zika virus-like particle comprising the polynucleotide, wherein the polynucleotide is not a Zika virus polynucleotide and the polynucleotide has a length of up to about 10,000 nucleotides.
4. The method of any one of claims 1-3, wherein the subject suffers from a disease or disorder of the central nervous system.
5. The method of any one of claims 1-4, wherein the polynucleotide has a length of greater than about 6000 nucleotides.
6. The method of any one of claims 1-5, wherein the subject is a human or a non-human animal.
7. A Zika virus or a Zika virus-like particle, comprising a polynucleotide exogenous to a Zika virus having a length of about 6,000 nucleotides to about 10,000 nucleotides, optionally wherein the polynucleotide does not encode a full-length viral structural protein or a full-length viral non-structural protein.
8. The method of any one of claims 1-6 or the Zika virus or Zika virus-like particle of claim 7, wherein the Zika virus or Zika virus-like particle is produced by a nucleic acid comprising the polynucleotide.
9. The method or Zika virus or Zika virus-like particle of claim 8, wherein the nucleic acid further comprises a Zika virus 5'UTR and a Zika virus 3'UTR.
10. The method or Zika virus or Zika virus-like particle of claim 9, wherein the Zika virus 5'UTR is at least 90% homologous or identical to the Zika virus 5'UTR of Table 2, Table 1A, Table 1C or Table 1H.
11. The method or Zika virus or Zika virus-like particle of claim 9 or claim 10, wherein the Zika virus 3'UTR is at least 90% homologous or identical to a Zika virus 3'UTR of Table 2, Table 1A, Table 1B or Table 1G.
12. The method or Zika virus or Zika virus-like particle of any one of claims 7-11, wherein the nucleic acid further comprises a polynucleotide encoding a first ribozyme.
13. The method or Zika virus or Zika virus-like particle of claim 12, wherein the nucleic acid further comprises a polynucleotide encoding a second ribozyme.
14. The method or Zika virus or Zika virus-like particle of any one of claims 7-13, wherein the nucleic acid comprises a polynucleotide encoding a derivative of Zika virus C, wherein the derivative of Zika virus C is a truncation of about or less than about 5, 10, 15, 20, 25 or 30 amino acids of Zika virus C.
15. The method or Zika virus or Zika virus-like particle according to any one of claims 7-13, wherein the nucleic acid does not comprise a polynucleotide encoding a Zika virus capsid protein (C) or a derivative of the Zika virus C.
16. The method or Zika virus or Zika virus-like particle of any one of claims 7-15, wherein the nucleic acid does not comprise a polynucleotide encoding a Zika virus viral membrane protein (prM / M) or a derivative of a Zika virus prM / M.
17. The method or Zika virus or Zika virus-like particle of any one of claims 7-16, wherein the nucleic acid does not comprise a polynucleotide encoding a Zika virus viral envelope protein (E) or a derivative of Zika virus E.
18. The method or Zika virus or Zika virus-like particle of any one of claims 7-17, wherein the nucleic acid does not comprise a polynucleotide encoding one or more non-structural (NS) proteins: (i) NS1, (ii) NS2A, (iii) NS2B, (iv) NS3, (v) NS4A, (vi) NS4B, (vii) NS5, or (viii) two or more of (i)-(vii).
19. The method or Zika virus or Zika virus-like particle of any one of claims 7-18, wherein the nucleic acid further comprises a promoter.
20. The method or Zika virus or Zika virus-like particle of any one of claims 7-19, wherein the nucleic acid comprises a sequence of Table 1A-1K, Table 2 or Table 3.
21. A nucleic acid composition comprising (i) a 5' untranslated region (5'UTR) of a first Zika virus, (ii) a 3'UTR of a second Zika virus, wherein the first Zika virus is optionally the same as the second Zika virus, and (iii) a polynucleotide exogenous to the first Zika virus and the second Zika virus.
22. The nucleic acid composition of claim 21, wherein the polynucleotide has a length of about 5,000 bases to about 10,000 bases.
23. A nucleic acid composition according to claim 21 or claim 22, wherein the nucleic acid does not include a polynucleotide encoding a Zika virus viral envelope protein (E) or a derivative of Zika virus E; and the nucleic acid does not include a polynucleotide encoding one or more non-structural (NS) proteins: (i) NS1, (ii) NS2A, (iii) NS2B, (iv) NS3, (v) NS4A, (vi) NS4B, (vii) NS5 or (viii) two or more of (i)-(vii).
24. The nucleic acid composition of any one of claims 21-23, comprising a sequence of Table 1A-1K, Table 2 or Table 3.
Citation Information
Cited By
A tick-borne encephalitis virus-derived circular RNA and application thereof in prevention and treatment of Parkinson's disease
CN122898520A
